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Background: South Africa has the most people living with HIV (PLWH) in the world. 
With increased access to HIV Counselling and Testing (HCT) as well as expanded 
Antiretroviral Therapy (ART) treatment guidelines; there is a large and increasing 
number of people who need access to HIV care. Limited data and few studies have 
evaluated access to HIV care. 
Methods: A cross sectional survey with stratified random sampling was conducted 
from January – April 2011 to determine the proportion of PLWH in urban areas in the 
greater Cape Town area who are accessing appropriate HIV care and factors associated 
with accessing care. The sampling frame for this study was the Zambia South Africa TB 
and AIDS Reduction (ZAMSTAR) Study. Self reported HIV positive adults were randomly 
selected. Self reported HIV negative adults or adults of unknown HIV status were also 
randomly selected in order to decrease possible stigmatisation. Consenting 
participants were interviewed and completed a questionnaire detailing their access to 
HIV testing and care. Participants who disclosed that they were HIV positive were 
included in the analysis. Access to appropriate HIV care was defined as one of three 
scenarios: 1. Receiving ART and having attended an ART clinic or collected ART 
medication within the last three months. 2. Undergoing ART work up and having 
attended an ART clinic within the last three months. 3. In PreART care having had a CD4 
count in the last 6 months. 
Results: 1257 participants were interviewed. 627(50%) reported being HIV positive, 
487(39%) HIV negative and 143(11%) did not know or wish to disclose their status. Of 
the 627 HIV positive participants: 392 (63%) reported taking ART of whom 369 (94%) 
accessed appropriate HIV care. 25 (4 %) were being worked up for ART of whom 16 
(64%) accessed appropriate HIV care. 210 (33%) were in PreART care, 81 (39%) having 
accessed appropriate HIV care. Females were 3.78 times more likely to be in 
appropriate care than males (p <0.001), and a person in the age category greater than 
45 years was 4.63 times more likely to be in appropriate care than someone in the age 












Conclusion: Access to appropriate care was high for those on ART; however for PreART 
care it was low. A systematic approach to PreART care with attention to client and 
service factors is needed. The impact on existing resources and the need for additional 
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South Africa has the most people living with HIV (PLWH) in the world. With increased 
access to HIV Counselling and Testing (HCT) as well as expanded Antiretroviral 
Therapy (ART) treatment guidelines; there are a large and increasing number of 
people who need access to HIV care. There is little information available on the 
proportion of PLWH in the Western Cape who are accessing care and the factors that 
are associated with this. To ensure that PLWH access HIV care, opportunities to target 
this group must be exploited.  
Research Question 
To identify factors associated with accessing appropriate HIV care in PLWH  
Setting and Population 
The study will be conducted in urban areas in the greater Cap  Town area where the 
Zambia South Africa Tuberculosis and AIDS reduction study (ZAMSTAR) TB and HIV 
prevalence survey has been conducted. These areas have a high prevalence of HIV 
and Tuberculosis (TB). The population will be individuals who have previously 
participated in the prevalence survey. 
Methods 
Self reported HIV positive adults will be randomly selected. Self reported HIV negative 
adults or adults of unknown HIV status will also be randomly selected in order to 
decrease possible stigmatisation.Individuals will be revisited and, after giving 
informed consent, they will be asked to complete a questionnaire which will detail 
their self reported HIV status, and in those PLWH if they have had a CD4 count and 
are in care, as well as factors thought to be associated with accessing care for HIV. 
Analysis 
Univariable and multi-variable analyses will be performed to determine factors 
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Significance  
This information may allow for informed suggestions to be made to health structures 
in the Western Cape to improve services within health care facilities and HCT testing 














1.1. Background to HIV prevalence and the roll out of HCT in South Africa 
South Africa has the largest Antiretroviral Therapy (ART) programme in the world with 
around 1 million people on ART by the end of 2009(1). However, South Africa also has 
the highest number of people living with HIV (PLWH) in the world with UNAIDS 
estimating that in 2009 there were 5.7 million people living with HIV in South Africa(1, 
2). Access to treatment is thus low(1) and in mid 2008 the number of adults with 
untreated clinical AIDS or CD4 counts < 200 cells/mm3  was 760 000(3). There is a 
large gap between the number of people undergoing HCT and those accessing ART. 
 
The target of the 2011 National Strategic Plan is to initiate 80% of those needing ART 
onto treatment by 2011(2). Prior to initiation of ART a large number of people will 
need to access PreART care and continue to access care until they are eligible for ART.  
 
Presently there is a focus on the provision and scale up of HIV Counselling and Testing 
(HCT), which is seen to be a critical element in the prevention as well as HIV care and 
treatment pathway(1). 
 
The goal of the HIV Counselling and Testing campaign (HCT), launched in South Africa 
in April 2010, is to test 15 million people for HIV by June 2011 and to refer them to 
care as needed(1-4). The campaign also aims to screen and appropriately refer people 
for TB and other chronic diseases such as diabetes and hypertension. One of the 
proposed outcomes of the HCT campaign will be that the diagnosis of HIV will take 
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1.2. Current Standard of Care for people living with HIV in South Africa 
The 2010 ART treatment guidelines state that ART should be initiated at a CD4 count 
of ≤350 cells/mm3 if  the patient is pregnant or co-infected with TB, otherwise 
initiation of treatment is recommended at a CD4 count <200 cells/mm3 or stage 4 
disease(5). These guidelines also recommend that in people not eligible for ART a six 
monthly CD4 count should be done at a preART or wellness clinic to determine when 
ART is indicated(5). Unfortunately there is no further information or guidance given in 
the guidelines about how to effectively manage this large group of patients who are 
not yet eligible for ART.  
1.3. The need to determine factors that impact on accessing HIV care 
It is essential that those that test HIV positive access care and have an initial CD4 
count, and thereafter regular monitoring with initiation of ART when needed, 
otherwise the full benefit of strategies such as the HCT campaign will largely be 
negated and the treatment gap for those needing ART but not accessing it will widen. 
 
The National TB research priorities for 2010 – 2011 have identified the need to study 
and evaluate leakages within the existing TB and HIV referral 
mechanisms in order to determine the extent to which co-infected patients are lost to 
ongoing care due to weaknesses in the referral system(6). HIV and TB are closely 
linked in South Africa. Understanding more about the group of people who know their 
HIV positive status but who are not in care will help to address this national research 
priority. 
 
It is important to identify not only the gaps, but also the opportunities, in order to 
target those that have not accessed care. One such opportunity may be to use any 
exposure that individuals have to health care facilities to target the group of PLWH 
who are not yet in care. It is important to know if exposure to health care facilities on 
a regular basis, defined in this proposal as at least once in the last 6 months, for 
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chance of accessing HIV care. This information could inform and guide decisions and 
strategies to target HIV positive individuals whenever they are exposed to a health 
care facility and to provide means to increase their access to HIV care.  
1.4 Current literature pertaining to Access to Care in PLWH 
Although many studies have looked at ways to increase scale up and uptake of HCT, 
as well as factors impacting on ART initiation, treatment adherence, and ART loss to 
follow up, little data is available about the gap between those who test HIV positive 
and access to HIV care in sub-Saharan Africa.  
 
In 2008 the South African National HIV Prevalence, Incidence, Behaviour and 
Communication Survey; found that 25% of people aged between 15 and 49 years had 
tested for HIV within in the last year(1). This rose to 37% in 2009 according to the 
2009 National Communication Survey(1). However, there were no data in this report 
as to how many accessed HIV care.  
 
A small number of published studies reported on loss to care in sub-Saharan Africa in 
people newly diagnosed with HIV(7, 8).  A study by Losina et al(7) in Durban, 
conducted in 2006-2007, investigated pre treatment loss to care in newly diagnosed 
HIV positive people in two sites in Durban. Nearly half of the cohort studied resulted 
in pre treatment loss to care with failure to obtain a CD4 count in 8 weeks following 
diagnosis. Factors influencing this included a distance from the health centre of 
greater than 10km, a history of being treated for TB, and referral for HIV testing by a 
health care provider as opposed to self referral. This would imply that exposure to 
health care services that result in TB treatment or referral for HIV testing could be 
negatively associated with accessing appropriate HIV care.   
 
Other factors that have been associated with pre treatment loss to follow up in 
Uganda were male sex and a low CD4 count(9) while factors for loss to follow up after 
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responsibilities(10). Male sex, unemployment and a low CD4 count predicted loss to 
care in patients who had received their CD4 counts and had been given an 
appointment for ART workup(7).  
 
A study by Ulett et al(11) looked at a retrospective cohort of patients in the United 
States and described, following HIV diagnosis, the linkage to outpatient treatment, 
ART initiation, and further retention in care. They found that delayed initial linkage to 
care was associated with older age and African American race. This study is, however, 
not generalisable to our population as the cohort comprised a large proportion (51%) 
of men who have sex with men (MSM), males (75%) and there was a high percentage 
of reported drug abuse (26%). 
 
The health care provider plays a vital part in ensuring that aft r HCT a person accesses 
care. In Cape Town, delay in TB diagnosis was more attributable to health care 
provider delay than patient delay(12). Given the high TB HIV co-infection rate this 
serves to highlight the need to look at health care provider related opportunities to 
channel people into care. 
 
This study seeks to determine factors that impact on PLWH accessing care for HIV 
across multiple sites in the greater Cape Town area. The population will be those who 
have undergone HCT and know their HIV status.  This will provide an opportunity to 
determine the proportion of PLWH who are accessing care. 
 
The aim is that by better understanding this population, strategies to prevent missed 
opportunities can be suggested.  
 
1.5. Research Question 















To determine whether the following factors impact on a person accessing care for 
HIV: 
• Attendance at a health care facility within the last six months for reasons other 
than HIV care 
• Self referral or provider initiated referral for HIV testing 
• Mode of transport and transport cost to access the clinic 
• Clinic waiting times 
• Current or previous treatment for TB 
• Age and sex 
• Education level 
• Employment status 
• Disclosure of HIV status to a partner or friend 
• Knowing a family member or friend who either had HIV, was on ART or who had 
died with HIV. 
 
Secondary Objectives 
To determine the proportion of PLWH who were accessing appropriate care: 
• Receiving ART and having attended an ART clinic or collected ART medication 
within the last three months of being interviewed  
• Undergoing work up in order to receive ART, and having attended an ART clinic 
within the last three months of being interviewed  
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2. Methods 
2.1 Study design 
The design is a cross sectional study. The study will form an addition to the ZAMSTAR 
Household TB and HIV Prevalence Survey (Ethics number NO4/10/173) which is 
summarised below.  
The ZAMSTAR TB and HIV Prevalence survey as a platform to study access to HIV 
care 
 
The Zambia South Africa TB and Aids Reduction (ZAMSTAR) study(13) is a community 
based study that has implemented innovative ways such as intensified TB case finding 
and Household contact tracing to decrease the prevalence of TB and HIV. The South 
African arm of the study is based at eight sites in the greater Cape Town area where 
there is a high prevalence of TB and HIV. The final outcome of the ZAMSTAR study is a 
prevalence survey of TB and HIV. In South Africa there is a target to survey 40 000 
adults across the eight sites. The sites comprise between one and two primary health 
care clinics and include a minimum number of 25 000 people in each area according 
to 2003 Census data. 
  
Electronic maps have been generated for each site and the Census Enumeration Areas 
have been randomly selected. The ZAMSTAR Prevalence Survey enumerates and 
enrolls all consenting adults from these randomized Enumeration Areas. An 
enrolment target of 5000 adults per site has been set. 
 
All participants in the ZAMSTAR survey give written informed consent which includes 
consent to a repeat visit by the research team. Once enrolled in the survey 
participants complete a questionnaire that focuses on their demographics, 
socioeconomic status, and medical history, specifically with regard to TB and HIV. 
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willing to disclose their status. Participants submit a sputum sample for culture for TB 
and are offered HCT. 
 
Interim data from the survey indicate that about 50% of participants enrolled know 
their HIV status, and about 13% of these report that they are HIV positive. It is 
unknown how many of these are in care for HIV.  
 
This proposal intends to address this knowledge gap and survey those participants 
who have disclosed that they are HIV positive to determine if they are in care for HIV 
and the factors associated with this 
 
2.2  Study Setting 
The study will take place in the urban areas of the greater Cape Town area where the 
ZAMSTAR prevalence survey is being conducted. These areas are within Kayamandi, 
Stellenbosch; Mbekweni, Paarl; Wallacedene; Delft South; Nyanga; Mzamomhle, 
Philippi; Site C, Khayelitsha; and Kuyasa, Khayelitsha. 
 
2.3 Population and Sampling 
2.3.1 Definitions 
Access to HIV Care refers to any of the following in PLWH: 
1. Receiving ART and having attended an ART clinic or collected ART medication 
within the last three months of being interviewed  
2. Undergoing work up in order to receive ART, and having attended an ART clinic 
within the last three months of being interviewed  
3. In those not on ART or undergoing work up (i.e. PreART), having had a CD4 count in 
the last 6 months  
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Known HIV Positive: An individual who says that he/she has previously tested for HIV 
and knows that his/her status is HIV positive.  
Pre treatment loss to care: An individual who has tested positive for HIV and has not 
accessed HIV care. 
Self referral for HCT: A person accessing HCT on their own as an independent 
initiative (as opposed to being offered or referred for HCT by a health care 
practitioner). 
Provider initiated HCT: HCT offered or recommended by a health care provider. 
 
2.3.2. Inclusion and exclusion criteria 
Inclusion criteria 
• Age ≥18 years 
• Previously enrolled in the ZAMSTAR TB and HIV prevalence survey 
• Informed consent given to complete a questionnaire for this study 
 
Exclusion criteria  
• Age <18 years 
• No  consent obtained for  the ZAMSTAR prevalence survey 
• An Individual that is living in an institutional setting (i.e. prisons, boarding 
schools, military camps, hostels and lodges) 
• Informed consent not able to be obtained due to the influence of alcohol or 
drugs or mental impairment 
2.3.3 Population 
The study population will be those who fulfill the inclusion criteria. In summary these 
are adults who have previously been enrolled in the ZAMSTAR TB and HIV Prevalence 
Survey and gave consent to be visited again by the research team. They will be 
revisited in this study, written informed consent will be obtained and consenting 
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study are participants who, during the ZAMSTAR survey, disclosed that they were HIV 
positive. However, in order to avoid stigmatization around HIV as well as to maintain 
confidentiality in the community,  a  proportion of participants who either disclosed 
that they were HIV  negative, or else did not know or wish to reveal their HIV status 
will be also be revisited.  
 
2.4 Sampling strategy 
A random sample of individuals who participated in the ZAMSTAR TB Prevalence 
Survey will be revisited by Research Assistants. 75% of this sample will be comprised 
of participants who disclosed that they were HIV positive, and 25% who disclosed that 
they were HIV negative or who had not disclosed their HIV status. 
Individuals will be allocated a unique barcode that will be different to, but will be able 
to be linked with the barcode that was allocated in the ZAMSTAR survey. 
 
The following procedure will be followed for determining the random sample: 
 
• Overall lists of participants that were enrolled in the ZAMSTAR survey will  
be generated per site – only unique bar code numbers will be used (no names).  
• Lists of the Enumeration Ar as (EAs) surveyed in the ZAMSTAR prevalence survey 
will be compiled per site. Half of these EA’s will be selected randomly and included 
in the sampling frame. 
• Lists of known HIV positive participants (from the ZAMSTAR prevalence survey) 
living in these randomly selected EAs, will be compiled using only unique bar code 
numbers (no names). 
• Lists of HIV negative participants or those who did not wish to disclose their status 
(from the ZAMSTAR prevalence survey) living in these randomly selected EAs, will 
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• Individuals will be randomly selected (using only unique bar code numbers (no 
names), from these EA’s so that for every 3 HIV positive participants there will be 
1 HIV negative participant.  
• Only after this selection, will the name and address be linked to the bar code to 
enable the research team to visit the identified participant.  
• EA’s will be visited in order, and all randomly selected individuals visited, until the 
required sample size is reached per site. 
 
The details from the ZAMSTAR study for the randomly selected individuals will be 
unlinked by the senior data manager so that names and addresses are available for 
each individual. Consent forms will be printed that include a new unique barcode, 
name and address. The barcodes from the ZAMSTAR study will not be printed on 
these consent forms. Research Assistants will then be given all the randomized 
individuals per EA per site to visit and to obtain informed consent to enroll in this 
study.  
 
Individuals will be enrolled if they give written informed consent and complete a 
questionnaire on accessing care that the Research Assistant reads out aloud.  (Access 
to Health Care Questionnaire: Appendix 1) This information will be captured on a 
Personal Digital Assistant (PDA) and the information downloaded on a daily basis at 
DTTC. The Research Assistant will scan the new bar code into the PDA so that there is 
no name on the questionnaire. The only place where name will occur will be on the 
consent form. 
 
2.4.1 Field Management 
Correct Identification of individuals in the field: 
The consent form that the individuals signed for the ZAMSTAR prevalence survey form 
indicated that staff from DTTC may visit the individual again at a later date. As 
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individual’s name, unique barcode and address will be printed. The Research Assistant 
will revisit the individual and confirm that the individual has been identified correctly 
by asking them to confirm their name and date of birth. 
 
The participant will be provided with an information sheet about this study and asked 
if they agree to take part in it. The consent form and information sheet will also 
document that the participant agrees that the study can access information that was 
recorded about them in the ZAMSTAR survey. If the participant agrees then they will 
sign the pre-barcoded consent form. (Information sheet and Informed Consent: 
Appendix 2+3). The RA will ask them the questions on the questionnaire and record 
the answers on a personal digital assistant (PDA). The questionnaire and data on the 
PDA will have a unique code and will not have any personal identifiers. 
 
If a participant is not at home, the Research Assistant will make a note on a 
management form as to the time and date of the visit (Management form: Appendix 
4). The Research Assistant will visit the house on two additional occasions at different 
times to try to locate the person. If after three visits they have not succeeded in 
finding the person then they will return the consent form having marked that they 
were unable to locate the person. 
 
All participants who disclose during the questionnaire that they are HIV positive and 
who are not accessing care for HIV will be given information as to the appropriate 
clinic to access care. They will also be offered a referral letter to go to the clinic to 
seek care.  
 
2.5 Sample size 
A minimum sample size of 632 PLWH will be needed to detect a 10% risk difference in 
attendance at a health care facility within the last six months for reasons other than 
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calculated using Open Epi , version 2, open source calculator for Cross sectional 
survey. 
 
The total sample size will include an additional 1 participant who is HIV negative or 
who has not disclosed their HIV status for every 3 PLWH. This is to avoid stigma 
related complications and to be able to assess the number of HIV negative individuals 
who are exposed to health care facilities. 
 
Assuming that 30% of participants are not able to be found or do not consent to take 
part in the study, and to allow for a design effect of 1.58 due to clustering, an 
additional 15% has been added to the required total, bringing the sample size to 945 
individuals who are known to be HIV positive. The total sample size, which includes 
315 individuals who are HIV negative or have not disclosed, will be 1260.    
 
In order to achieve recruitment of the sample size eight research assistants (RA) will 
need to work in four of the eight sites at any one time, in teams of two RA’s per team. 
Given a conservative estimate that each team can enroll 6 people per day, five days 
per week in four sites, then the sample size will be reached in three months. 
 
2.6. Data Management 
All informed consent forms will be coded with a unique barcode that will be able to 
be linked to the ZAMSTAR barcode for the individual by the data manager.  
 
If the participant gives informed consent and signs the consent form, the barcode on 
the consent form will be scanned into the PDA and the answers to the questionnaire 
captured on the PDA. No name will be linked to the data on the PDA. The information 
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The informed consent forms will be scanned in daily at DTTC. The name of the 
participant and the barcode will be captured electronically and saved on the DTTC 
central database. All data is backed up onto a second server on a daily basis. Data 
from the ZAMSTAR Prevalence survey will to be linked to the data on the PDA via the 
unique barcode. This will only be able to be done by the data manager. The name of 
the individual will only appear on the consent form. The senior data manager will be 
the only person who can link the name from the consent form via the unique barcode 
to the data. The consent forms will be stored in locked steel cabinets. 
2.7 Data dictionary 
 See appendix 8 
2.8. Quality Control 
Research Assistants will be trained by the Principal Investigator, the study coordinator 
and the data team to accurately record the answers to the questionnaire on the PDA. 
The study coordinator will randomly select 5% of the completed consent forms on a 
weekly basis for a home visit to ensure that participant was enrolled as per protocol in 
the survey as an additional quality control measure. During that visit the signature of 
the participant will be confirmed.  
 
2.9. Potential Strengths and Weaknesses of the study 
2.9.1 Weaknesses 
There may be a selection bias in that some known HIV positive participants in the 
ZAMSTAR study will be unwilling to disclose their status to the Research Assistant 
conducting the ZAMSTAR prevalence questionnaire. These participants may therefore 
never be interviewed or enrolled in this study. It is possible that these participants are 
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There will be recall bias as all the data will be self reported and the answers for some 
questions may need recall from a long time ago. Where possible the validation of 
answers from the participants HIV clinic card will be included. 
 
2.9.2 Strengths 
A large sample size is required, and it is probable that a wide distribution across sex, 
age, education and health status will be obtained.  
Data from the ZAMSTAR Prevalence survey Household and Individual questionnaires 
(ZAMSTAR Individual and Household Questionnaire: Appendix 5) will be collated with 
information collected in this study. This will give additional information that can be 
used to predict factors influencing access to care. 
  
This study is targeting individuals in the community. Selection bias is minimized, as 
many other studies focusing on access to care, or loss to follow up care, select their 
population from a clinic as opposed to the general population. 
This study collects data directly from individuals and not from folder reviews, 
therefore missing data as a result of a folder review design will be negated. 
 
3. Statistical Analysis 
All data will be exported into and analyzed in STATA version 11.0. The sample will be 
described according to the individual’s demographics and HIV testing pathways in 
numbers and percentages. The number and percentage of participants accessing 
appropriate care, as per the study definition, will be determined. Associations 
between the HIV positive and negative groups will be described using the chi-square 
test of independence. Factors that are thought to impact on access to care will be 
described in numbers and percentages and a untivariable analysis of these factors will 
be conducted.  A multivariable analysis using a logistic regression model will be 
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4. Ethics and communication 
4.1 Ethical considerations 
Ethics approval will be obtained from the Stellenbosch University Committee for 
Human Research and the research will be conducted according to the Helsinki 
Declaration. Ethical clearance will also be obtained from the Ethics advisory group of 
the International Union against TB and Lung disease (The Union) and the Health 
Sciences Human Research Ethics Committee at the University of Cape Town. 
The autonomy of the participants will be respected by providing information in a 
written information sheet (Information sheet and Informed Consent: Appendix 2+3) 
and answering any questions that they have regarding the aims and nature of the 
study. The participant will be free to decide whether or not to participate in the study 
without being coerced. Should they decide to participate in the study, their written 
informed consent will be obtained (Information sheet and Informed Consent: 
Appendix 2+3)   
Participants will be assured that any personal information will be kept confidential. 
Data will be captured on a PDA using a unique barcode and the database will not 
contain any personal identifiers. The senior data manager will be the only person who 
can link the name from the consent form via the unique barcode to the data.  
 
The interview will be conducted in the language (English, Afrikaans or Xhosa) that the 
participant is most comfortable in. There will be no financial incentives awarded to 
the participants. 
Participants may feel vulnerable about disclosing their HIV status to the RA, even 
though the majority would already have volunteered this information in the 
ZAMSTAR prevalence survey. They may feel distressed by recalling their experiences 
as to when they were first diagnosed with HIV. In order to alleviate distress all 
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comfortable with, and are free to withdraw from the study at any time. The RA’s will 
be trained in Good Clinical Practice and will understand the importance of 
maintaining confidentiality. Where possible, at least one RA per team will also have 
been trained in HIV counselling.  
After completing the questionnaire, those participants who have not accessed care, 
will be informed about the importance of accessing care and will receive counselling 
around issues of HIV, should this need arise. All participants will receive information 
on HIV, CD4 Counts, and HIV care in the community – as stated in the Information 
sheet and Informed Consent Form. 
All participants will be given the contact details of the study managers, where they 
can direct questions relating to the study or to their rights as study participants.  
4.2 Dissemination of results 
The findings from the study will be presented at the annual DTTC dissemination 
meeting attended by members from the community advisory boards as well as by 
clinic staff and colleagues from the City and Provincial Health departments. 
A summary of the findings of the study will be compiled and given to the facility 
manager of the clinics to distribute to staff. 
Results will be communicated both personally and in a written summary to local 
stakeholders. These are the City of Cape Town and Provincial Health Department.The 
results will be written in a scientific article and sent to a peer reviewed journal for 
publication. Results will also be submitted to the South African TB and HIV conference 
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5. Logistics 
5.1 Budget  See Appendix 6 
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PART B LITERATURE REVIEW 
ACCESS TO CARE IN PEOPLE LIVING WITH HIV 
 
1. Introduction and Objectives 
The following literature review focused on access to appropriate HIV care for People 
Living with HIV (PLWH). The burden of HIV, as well as the current standard of care and 
guidelines for appropriate care in South Africa, is described. Particular attention was 
paid to recent studies that have been based in South Africa as the extent to which 
PLWH have access to care and the associated factors will often be influenced by 
demographic, geographical, cultural and political factors, and so the most value from 
this study would be to the South African Policy makers, thus the focus on South African 
literature. The literature presented is categorized according to set time points in the 
HIV pathway where access to care has been studied. The need for further research in 
this arena is also addressed.  
The concept of Access to care in people living with HIV aims to describe those persons 
with HIV in different points of their HIV pathway who are accessing the appropriate 
care, and this encompasses availability, affordability, accessibility as well as utilization 
of health care services.  
2. Search Strategy and Inclusion and Exclusion Criteria 
A search for articles in English published between 2000 and 2011 that related to access 
to care in PLWH was performed by searching PubMed and Google Scholar. 
Quantitative and Qualitative studies were included. Systematic review articles were 
included, but case reports and case series were not. In addition to this, the reference 
lists of applicable studies were scrutinized for additional relevant citations. All the 
studies that were included were published in peer reviewed journals. Although the 
initial search strategy included both developed and developing countries, studies 
pertaining to access to care in PLWH focused on South Africa and sub-Saharan Africa 
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pertaining to the validity of self reported HIV status both developed and developing 
countries were included. 
For literature pertaining to Access to HIV care the search terms used included: HIV (or 
Human Immunodeficiency virus) OR CD4 count or CD4 testing or ART (or Antiretroviral 
therapy) AND” linkage to care” OR “loss to follow up” OR “access to HIV care”. 
WHO reports, UNAIDS reports and documents from the South African National 
Department of Health were sourced via their respective websites for information 
pertaining to the Background and Current Standard of Care sections. Terms that were 
used to gather additional  information about background and current guidelines 
included HIV, Voluntary Counselling and Testing (VCT), HIV Counselling and Testing 
(HCT), CD4 testing, ART (or antiretroviral therapy) AND South Africa. 
For literature concerning the Validity of self reported HIV status search terms included: 
“Knowledge of HIV status “OR “CD4 count” OR “Self disclosure” AND “validity” OR 
“reliability”. 
 
3. Study quality and relevance 
Of the twelve quantitative studies that dealt with Access to Care, four were 
prospective cohort studies and eight were retrospective cohort studies. The central 
theme of the studies was loss to care in the time period before antiretroviral therapy 
(ART) initiation (PreART). In all the studies there was loss to follow up of participants 
and it was not possible to ascertain whether a patient truly failed to access care, or 
rather sought care after the stipulated timeframe, or at another facility. This was a 
particular problem with retrospective studies but it also depended on the quality of the 
health information tracking systems that were in place. 
One systematic review that investigated PreART retention in care in Africa(1) was 
included. This review was used to identify additional studies that were of relevance as 
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core question of , “What proportion of patients who test positive for HIV are staged, 
enroll and remain in preART care until eligible for ART, and initiate ART” was not 
answered by the systematic review(1), and hence the need for this study. 
 
4. Summary of the literature 
4.1. Background to the burden of HIV in South Africa and the need for access to HIV 
care 
South Africa has the greatest HIV epidemic in the world with an estimated 5.6 million 
PLWH in 2009(2). This requires appropriate HIV care for those afflicted. This care needs 
to be tailored for different time points as indicated by the natural lifecycle of the 
disease.  
 
The provision of appropriate HIV care depends on a series of steps that incorporate the 
need for initial diagnosis of HIV, monitoring of the CD4 cell count, treatment of HIV-
related illnesses until the stage is reached where ART is indicated, and thereafter 
initiation and maintenance on ART.  
 
Initial HIV diagnosis should be as early as possible, so that the index case can be 
empowered to reduce ongoing transmission as well as live positively with HIV(3, 4). 
Initiation on ART should also be timely as mortality is strongly associated with CD4 cell 
counts below 50 cells/mm3, or Stage 4 disease at ART initiation(5). Strategies to reduce 
HIV related mortality need to include earlier diagnosis of HIV, strengthening of PreART 
HIV care and prompt initiation of ART(5-7). 
The overall goal of treatment programmes that deliver HIV care are: Early diagnosis of 
HIV infection; prompt enrollment in PreART care, appropriate monitoring and care 
prior to ART eligibility; timely initiation of ART; ensuring survival through the early 
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The HIV and AIDS and STI National Strategic Plan for South Africa 2007 – 2011  has 
been developed to identify interventions to reduce the incidence of HIV, as well as the 
impact that HIV has on the lives of individuals, as well as their families and 
communities(9). An important component of the plan is that it sets targets with regard 
to these interventions. The target was set to reduce the national HIV incidence rate by 
50% by 2011, and to provide an appropriate package of treatment, care and support 
services to 80% of PLWH by 2011(9). 
4.2 Current Standard of Care for PLWH in South Africa 
1. HIV Counselling and Testing (HCT) 
The entry into appropriate HIV care begins with the knowledge of HIV status. As the 
epidemic progresses and the way in which it is managed changes, there are new 
opportunities to expand access to HCT(10). Many different strategies are incorporated 
into the 2007 – 2011 NSP which aims for 70% of South Africans to have tested at least 
once for HIV, and furthermore 25% of the population to test annually by 2011(9). HCT 
for HIV has expanded rapidly in the last few years with 7 million adults (aged 15 years 
and older) having received HCT in 2009(11). 
 
Another initiative that ensures the increase of HCT has been the launch of The HIV 
Counselling and Testing Campaign in 2011, which aimed to test 15 million people for 
HIV by June 2011 and to refer them to care as needed. The target for the Western Cape 
was 1,1 million people over the age of 12 years who were sexually active(12). The 
campaign aimed to increase the incidence of appropriate health seeking behaviour, as 
well as access to treatment, care and support. Although the final figures are not yet 
available,  the South African Health Minister, Dr A Motsoaledi,  announced in his 2011 
health budget policy speech that 11.9 million people had tested for HIV since the 
launch of the campaign(13). 











Page 34 of 120 
 
Once the diagnosis of HIV has been established, CD4 cell count monitoring and HIV 
staging needs to occur at regular intervals in order to establish when the person should 
commence ART. According to the 2010 ART treatment guidelines CD4 cell count 
monitoring at a preART or wellness clinic should occur at six monthly intervals if a 
PLWH is not yet eligible for ART(14). The guidelines fail however to give more insight 




The 2010 ART treatment guidelines stipulated that initiation of ART should occur if the 
CD4 cell count was «350 cells/mm3 if the patient was  pregnant or co-infected with 
Tuberculosis (TB), otherwise ART was recommended at a CD4 count of« 200 cells/mm3, 
or stage 4 disease(14). These guidelines fell short of the WHO recommendations that 
all patients initiate treatment at a CD4 cell count of «350 cells/mm3(15). The guidelines 
were amended in 2011 to state that all patients with a CD4 count of «350 cells/mm3 
initiate treatment(16). 
 
4.3 Validity of self reported HIV status 
Access to appropriate HIV care can either be determined through routine or research 
orientated monitoring programmes that track patients at any point from the time of 
initial HIV diagnosis to ART initiation, or it can be self reported by the patients. There is 
limited data available, especially in developing countries, as to the validity of a person’s 
self reported HIV status and other self reported HIV measures like CD4 count as 
compared to the clinical records.  
In developed countries a study found that amongst IV drug users only 68% of HIV 
positive participants accurately reported their HIV status, whereas 98% of HIV negative 
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however  to be reliably and validly assessed through self reporting in PLWH, especially 
in those with a higher education level(18). 
A study conducted in Cape Town(19) showed that self reported HIV status is likely to 
be understated as well as the prevalence of unprotected sex amongst married or 
cohabiting couples.  
4.4 Literature review of articles pertaining to Access to Care in PLWH 
 
Studies pertaining to time points at which linkage to care have been reported 
 
The majority of programmes report the number of people initiated on ART(20). 
Recently there has been limited data reporting on other time points related to linkage 
to care in Sub-Saharan Africa(21-23). Studies from developed countries were not 
included as the patient population is very different. In developed countries population 
groups differ substantially with regard to socioeconomic status and mode of HIV 
acquisition, with a higher percentage of HIV acquisition linked to IV drug abuse and 
homosexual sex(24). Factors associated with linkage to care in these contexts would 
not be generalisable to South Africa.  
 
In a systematic review by Rosen & Fox(1), which looked at retention in HIV care before 
initiation of ART, the following time points were identified: Stage 1: The patient is 
staged for referral to either PreART or ART care. This includes CD4 testing after initial 
HIV diagnosis and collection of results. Stage 2: From enrollment in HIV care until 
eligibility for ART. Stage 3: From establishment of ART eligibility until ART initiation. 
They report that these steps were often poorly defined in the literature and vary 
widely, especially where a certain time is allocated for a step to occur, e.g. collection of 
CD4 results, or where eligibility is a factor, e.g. eligibility for ART. This wide variation is 
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different NGO’s or government departments which have their own criteria and goals 
for patients in their care.   
 
For this literature review, studies were categorized according to the three stages as 
reported by Rosen and Fox(1) in order to standardize definitions of linkage to care, as 
has been recommended in their systematic review. Some studies looked at only one 
point whilst others reported a combination. No study looked at linkage to care across 
all time points. 
 
Studies pertaining to Stage 1: Patients staged for PreART or ART HIV care 
 
Kranzer et al(21) looked at linkage to HIV care in individuals testing at different sites in 
a community in Cape Town. They looked at clinical and laboratory records for a 
random sample of HIV positive patients (n=988) and found that 63% (n = 621) went for 
a CD4 test within 6 months of testing and 26% (n=255) had no record of a CD4 count 
result. Patients most likely to return for CD4 count testing were those that tested for 
HIV at antenatal care and sexually transmitted infection (STI) services. It was lowest 
amongst those that were self referred for HIV testing.  
 
Losina et al(22) looked at pre treatment loss to care (PTLC) in newly diagnosed HIV- 
positive people in two sites in Durban. They defined PTLC as failure to obtain a CD4 
count within 8 weeks following HIV diagnosis. Nearly half of the cohort (45%)  (n=206) 
did not collect their result within 8 weeks. Factors associated with PLTC included a 
distance from the health care centre of greater than 10km, a history of being treated 
for TB, and referral for HIV testing by a health care provider as opposed to self referral.  
Larson et al(25), in a similar study at a public sector HIV clinic in Johannesburg, 
determined the proportion of HIV-infected persons that had a CD4 cell count taken and 
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completion was 35% (n=122/352). A higher baseline CD4 cell count (>200 cells/mm3) 
was associated with a lower odds of CD4 testing completion. 
 
Data from an HCT folder review of 634 positive HCT clients, during  a routine annual 
HIV/TB/STI evaluation in Cape Town, found that 77.5%  had a CD4 count taken(26). It is 
not known how many clients had returned for their results. 
 
These studies showed a wide range (35% - 63%) in the number of clients returning for a 
CD4 count after initial HIV diagnosis. Associated factors included the type of referral 
system within the facilities (self referral for HIV testing as opposed to health care 
provider referral), distance that the patient had to travel to the health centre, a 
previous history of TB and the progression of HIV disease as indicated by a lower CD4 
count. 
 
Studies pertaining to Stage 2: From enrollment in HIV care until eligibility for ART 
 
Retention in HIV care, and associated factors in individuals not yet eligible for ART,  was 
determined by Lessells et al(23) in rural KwaZulu – Natal, South Africa. Participants 
were older than 16 years and ART naive with an initial CD4 count>200 cells/mm3. Of 
the 4223 included in the analysis, the overall retention, defined as returning for a 
follow up CD4 count within 13 months was 45% (n=1896). In addition 72% (n=1371) 
returned only once for a follow up CD4 count. Factors associated with higher retention 
were a lower initial CD4 count, older age and female sex. In a subset analysis where 
individuals were matched to the Africa Centre Demographic Information system 
(ACDIS) male sex, higher baseline CD4 count, out migration (patients who were initially 
resident in the demographic surveillance area but became non-resident during the 13 
month study period), full time employment, and a household size of more than 10 
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In Johannesburg at a public sector PreART care programme LTFU was determined 
between initial enrollment and the first scheduled follow up medical visit(25). They 
found that 74% of patients (n=169/228) with a CD4 count >350cells/mm3 who were 
scheduled to return within 6 months had not returned within one year. Only 6% 
(n=8/128) of the patients that had a CD4 count between 251 and 350, and who were 
scheduled to return within 3 months kept their appointment within a 4 month period, 
and only 41% (n=53/128) had returned within a one year period(25). Employed 
patients were more likely to return, as were those with a lower CD4 count (CD4 251-
350cells/mm3). 
 
These two studies indicate a high proportion (55%-74%) of LTFU after an initial CD4 
count. Associated factors include the progression of HIV disease as determined by a 
lower CD4 count as well as gender, age and employment status. 
Studies pertaining to Stage 3: From establishment of ART eligibility until ART 
initiation 
 
Kranzer et al(21), reported that  only 67% (n=147) of those who returned for a  CD4 
count within 6 months of HIV diagnosis and who were eligible for ART (defined as a 
count of 200 cells/mm3 or less),  were initiated on ART within 6 months of their HIV 
diagnosis. Linkage to care in this group was highest amongst those testing through 
antenatal care. 
 
A study in Durban examined the loss to care and mortality rates before starting ART in 
ART eligible HIV-infected patients(27). They found that 16% (n=82) were lost before 
ART initiation with 34% (n=28) having been confirmed as having died. Loss to care was 
associated with lower baseline CD4 counts as well as unemployment. The study 
population differed from other programmes in South Africa as the patients had to pay 
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In a large prospective cohort study in the Free State, South Africa, differences in access 
and patient outcomes across ART treatment clinics were assessed(28). 45000 ART 
naïve patients were enrolled in the study between May 2004 and December 2007. The 
odds of starting ART improved over calendar time. Overall they found that by the end 
of 2008, 34% of eligible patients had started ART within 1 year of enrollment. Factors 
associated with not initiating treatment included male sex, CD4 count below 50 
cells/mm3, weight below 50kg, and distance to the clinic of greater than 15km. PreART 
mortality was high with the majority of deaths in the cohort (83%) occurring in patients 
not yet on ART.  
 
In an prospective study in Uganda where patients who were eligible for ART were 
followed up to see if they completed three screening visits required prior to initiating 
ART(29), they found that 26% (n=637) did not complete screening and did not start 
ART. Associated factors included male sex and a low CD4 count. Pre treatment 
mortality was high with 28% (n=181) having died at a median follow up of 351 days. 
The high cost of transport was a reason given by many who later returned for follow up 
(n=70/158). 
 
These findings are corroborated by provisional data by Togun et al(30) in a study from 
the Gambia which found that a third of people eligible to start ART (n=254/790) did not 
do so, and of these 15%  (n=118/790) were confirmed as having died. Predictors of pre-
treatment mortality were a low CD4 count (<100 cells/mm3) and WHO stage 3 or 4 
disease. A barrier to ART initiation that was cited by 40% of those lost to follow up who 
were traced by the research team was the requirement to disclose their HIV status 
prior to ART initiation.  
A study in Malawi looked at LTFU up after initial screening for ART eligibility(31), and 
found that 13.9% of eligible patients (n=88/633) defaulted before starting ART. There 
was a high mortality amongst this group with 58% of those who defaulted and who 
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their scheduled follow up ART appointment. Factors associated with defaulting 
included lower education, difficulties in dressing, and a follow up ART appointment of 
more than one week.  
 
In Ethiopia the effect of improved availability of HIV services on PreART and on ART 
outcomes was studied by Mulissa et al(32). In the cohort 25% were lost to care before 
ART initiation (n=549/2191). Factors associated with LTFU included a less advanced 
WHO HIV staging as well as living in a rural area. 
 
High rates of TB HIV co-infection is a particular concern in South Africa with 58% of TB 
patients who tested for HIV in 2009 being HIV positive(33). Pepper et al looked at 
barriers to initiation of ART in HIV infected TB patients in an integrated TB HIV health 
care service in Cape Town. Of the 100 patients eligible to be assessed 66% initiated ART 
treatment during TB treatment. Factors that were found to be associated with failure 
to initiate ART included male sex, and younger age. 
 
Qualitative studies explored factors associated with linkage to and retention in HIV 
care. In a study in Rural Tanzania, where in depth interviews and focus group 
discussions with PLWH who had been referred to an ART clinic were conducted, health 
related beliefs and perceived barriers and benefits associated with regular clinic 
attendance were explored(34). They found that perceptions of susceptibility to HIV 
related illnesses as well as the presence of physical symptoms that reinforced this 
perception of susceptibility were important in determining who attended clinic 
appointments. Barriers included health system factors like distance to the clinic, as well 
as long journey times and long waiting times to be seen by the clinic staff. These 
findings largely corroborate the findings of factors in the quantitative studies. 
 
There was a wide range of loss to follow up prior to initiation of ART, and timeframes 











Page 41 of 120 
 
majority of the above studies is that PreART mortality was high and that a lower 
baseline CD4 count was associated with not initiating treatment. 
 
4.5 Limitation of studies included in the literature review 
 
Few studies have been completed that look specifically at access to HIV care in PLWH. 
There has also been no longitudinal study that spans the time from HIV diagnosis until 
initiation onto ART. 
 
 Although the studies have been summarized according to stages 1-3, as defined by 
Rosen & Fox(1), there was a wide variation in the time points that pertained to specific 
outcomes. E.g. the time frame from when a patient tests HIV positive and goes to 
collect their result (stage 1) differed across all three studies(21, 22, 25). Some studies 
looked at only one time point(22, 35), whilst other studies looked at more than one 
time point(21, 28). No study, however, looked comprehensively at all time points from 
testing for HIV until initiation on ART. There were also different definitions for Linkage 
to Care or Loss to Follow Up, depending on what organization was managing and 
providing the HIV services.  
 
The majority of the quantitative studies (eight out of twelve) were from patient 
populations in South Africa. Although this forms a solid research base from South 
Africa, which is also the country of interest to the researcher, it means that results will 
not be fully generalisable to Sub Saharan Africa. In addition to this, the majority of 
studies, even in South Africa, reported on different HIV programmes, many supported 
by different Non Governmental Organizations or academic units which further led to 
non generalisabilty of results. 
 
Factors that impacted on access to care differed widely across the studies, and their 
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patient employment status, gender, CD4 count, to factors from the individual health 
programmes, like referral patterns leading to referral for HIV testing and time between 




The above literature review has given an account of findings from studies that  have 
evaluated access to HIV care prior to the initiation of ART.  
Gaps in the literature include the need for a longitudinal study to be done spanning the 
time from HIV diagnosis until initiation onto ART as well as a need for ongoing 
identification and analysis of factors that are associated with accessing appropriate HIV 
care, both from within the health care system and on an individual patient level 
 
A challenge for many studies has been the absence of established patient data tracking 
systems to determine which patients are successfully accessing care. Future studies 
may benefit from utilising other methods of determining access to care, such as self 
reported health seeking behaviour. 
 
Future studies will add to the current knowledge and may facilitate strategies to be 
tailored to target those who currently fall through the gaps or experience unnecessary 
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ACCESS TO CARE IN PEOPLE LIVING WITH HIV 
Abstract 
Introduction: Limited data and few studies have evaluated access to appropriate HIV 
care (AHC). 
 Methods: A cross sectional survey with stratified random sampling was conducted 
from January – April 2011 to determine the proportion of People Living with HIV 
(PLWH) in urban areas in Cape Town who are accessing AHC and associated factors. 
Self reported HIV positive, negative or participants of unknown status completed a 
questionnaire around access to HIV care. Participants who disclosed that they were HIV 
positive were included in the analysis. Access to AHC was defined as one of three 
scenarios: 1. Receiving ART and having attended an ART clinic or collected ART 
medication within the last three months. 2. Undergoing ART work up and having 
attended an ART clinic within the last three months. 3. In PreART care having had a CD4 
count in the last 6 months. 
Results: 1257 participants were interviewed. 627(50%) were HIV positive, 487(39%) 
HIV negative and 143(11%) did not know or disclose their status. Of the 627 HIV 
positive participants: 392 (63%) reported taking ART, 369 (94%) accessed AHC.25 (4 %) 
were being worked up for ART, 16 (64%) accessed AHC. 210 (33%) were in PreART care, 
81 (39%) accessed AHC. Females were 3.78 times more likely to access AHC than males 
(p <0.001), and a person in the age category greater than 45 years was 4.63 times more 
likely to access AHC than someone in the age category 15-24 (p= 0.002). 
Conclusion: Access to AHC was high for those on ART; however for PreART care it was 
low. A systematic approach to PreART care with attention to client and service factors 
is needed.  
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Introduction 
 South Africa has the largest HIV epidemic in the world with an estimated 5.6 million 
people living with HIV (PLWH) in 2009(1). This necessitates care for a large and growing 
number of people. This care needs to be tailored for different time points as indicated 
by the natural lifecycle of the disease, and includes monitoring the CD4 cell count, 
treatment of HIV-related illnesses and initiation and maintenance on Antiretroviral 
Therapy (ART). There has been a strong drive to increase the numbers of people testing 
for HIV and  to provide the appropriate package of treatment, care and support to 
PLWH(2). Mortality however remains high in patients known to be HIV positive but not 
yet having accessed ART(3) and there is evidence that the level at which people initiate 
treatment is well below the recommended threshold(4, 5). Improvement in access to 
appropriate HIV care is essential if a lowering in mortality prior to ART initiation is to be 
achieved.  
 
The current standard of care for PLWH in South Africa includes: 1. HIV Counselling and 
Testing (HCT): The2007-2011 HIV, AIDS and STI National Strategic Plan  (NSP) aims for 
70% of South Africans to have tested at least once for HIV, and for 25% of the 
population to test annually by 2011. 2. PreART care: CD4 cell count monitoring at a 
PreART clinic should occur at six monthly intervals in those not yet eligible for ART(6). 
3. ART care: The South African National Department of Health’s 2010 clinical guidelines 
(amended September 2011)(7) stipulate that all patients with a CD4 count 
«350cells/mm3 are eligible to initiate ART.  
 
Many programmes providing care for PLWH report the number of people initiated on 
ART and the retention in care on ART(8) but there is limited data reporting on other 
time points related to HIV care in Sub-Saharan Africa(9-11). In this study we aimed to 
describe the proportion of PLWH who were accessing appropriate care and to 
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Methods  
Setting and population 
This study was conducted in eight communities in the greater Cape Town area. All the 
participants had previously taken part in a TB and HIV prevalence survey in 2010 as 
part of the Zambia South Africa TB and AIDS Reduction (ZAMSTAR) study(12). In the TB 
and HIV prevalence survey the participants had completed a questionnaire, been 
offered HIV testing and had tested for TB through sputum culture. About 33000 people 
living in randomly selected Census Enumeration Areas in each of the 8 communities 
were enrolled. All communities had a high burden of HIV and TB. The self disclosed HIV 
prevalence from the ZAMSTAR Prevalence survey ranged from 12-19% across the 
communities (Mr Rory Dunbar, personal communication). All communities are served 
by at least one public sector primary health care facility within a 5km radius of the 
homes of the participants, which offers HIV testing, PreART and ART care.  
 For this study a random group of participants (≥18 years old)  whose self reported HIV 
status from the TB and HIV prevalence survey was positive, negative or unknown, were 
revisited and asked to complete a questionnaire that focused on access to appropriate 
HIV care. Participants who had disclosed that they were HIV negative or did not know 
their status were included in the revisit in order to decrease stigmatization that may 
have resulted from only enrolling self disclosed HIV positive people. Participants who 
disclosed that they were HIV positive were included in the analysis. 
 
Study design and data collection 
All data is self reported. Data were collected from two sources. Firstly, variables were 
used from the ZAMSTAR questionnaire which had been completed at the time of the 
TB prevalence survey. These were age, sex, race, years lived in the area, and history of 
previous TB treatment. Secondly, data were collected from the cross sectional 
household study described here and conducted between February and April 2011. In 
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HIV care. Trained research field-workers visited participants in their homes where they 
interviewed them in their home language and completed the access to care 
questionnaire. The research field workers were unaware of the participants HIV status. 
They attempted to locate a person at least three times, once being after 4pm or over 
the weekend.  Data were recorded on an electronic personal data assistant (PDA) and 
downloaded on a daily basis onto a server at the Desmond Tutu TB Centre (DTTC). Data 
from these two sources (the ZAMSTAR and Access to Care questionnaires) were 
merged for the same individual based on unique barcode identifiers in order to identify 
variables associated with appropriate HIV care.  
As many participants as possible were enrolled during the same time period. A 
minimum sample of 632 PLWH was required to detect a 10% risk difference in 
attendance at a health care facility within the last six months for reasons other than 
HIV care with 95% significance level and 80% power. 
 
Definitions  
Access to appropriate HIV care was defined, according to our own study definition, as 
one of three scenarios. 1. Receiving ART and having attended an ART clinic or collected 
ART medication within the last three months of being interviewed. 2. Undergoing work 
up in order to initiate ART, and having attended an ART clinic within the last three 
months of being interviewed.3. In those not on ART or undergoing work up (i.e. 
PreART), having had a CD4 count in the last 6 months.  
 
Ethics 
 All participants had given written informed consent when enrolled in the ZAMSTAR 
Prevalence survey which included consent to be visited again for follow up studies. All 
participants gave written informed consent for the Access to Care Study. The study was 
approved by the Stellenbosch University Committee for Human Research, the Ethics 
advisory group of the International Union against TB and Lung disease (The Union) and 















Stata version 12 (Stata Corp.LP, College Station, TX, United States of America) was used 
for all analyses. Standardization was used to account for the sex ratio of HIV prevalence 
in the Western Cape according to the ASSA model(13). Logistic regression with robust 
standard errors to control parameter estimates for clustering at a community level was 
used to explore factors associated with receiving appropriate HIV care. This was used 
for univariable and multivariable analyses.  Factors that were explored using 
univariable regression to see if they impacted on the likelihood of a person accessing 
appropriate HIV care were: sex; age; employment status; highest education level; years 
living in the same area; referral mechanism of last HIV test; history of previous TB 
treatment; mode of transport and cost to access the clinic at their last visit, overall 
waiting time at the clinic; and knowing someone close to them who either had HIV, 
was on ART or had died with HIV. Significantly associated risk factors that were 
identified were then introduced into a respective multivariable model with variables 
being retained in the final model if associated likelihood-ratio test showed a P 
value<0.052 
Results  
1547 participants were selected from the ZAMSTAR prevalence survey. These 
comprised randomly selected self reported HIV positive participants (n=969), randomly 
selected self reported HIV negative participants (n=503) and randomly selected 
participants of unknown HIV status (n=75). There was a response rate of 81% (n=1257) 
(Figure 1). Of those who consented and were enrolled 627(50%) self reported that they 
were HIV positive, 487(39%) that they were HIV negative and the remaining 143(11%) 
either did not know or wish to disclose their status.  
Table 1 presents the demographic and HIV testing characteristics of the HIV negative 
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to 86% of the HIV positive participants (p<0.000). 54% of the HIV negative participants 
were unemployed as compared to 63% of the HIV positive participants (p=0.002). 
 
CD4 counts:  
Of the 627 participants who were HIV positive 97% (n= 608) had had a CD4 count 
(Table 2). 83% (n=506) of participants knew the value of their CD4 count, and when 
asked if their recollection was precise or an estimate, 70% (n=353) reported it to be 
precise. 84%of participants (n=510) said that they had had more than one CD4 count. 
 
Access to appropriate HIV care:  
Of the 627 HIV positive participants 63% (n=392) said that they were taking ART of 
which 94% (n=369) reported that they had attended a clinic within the last three 
months for treatment (Table 3).  4% (n=25) of participants reported that they were 
being worked up for ART, with 64% (n=16) having attended an ART clinic as part of this 
work up process in the last three months. 33% (n=210) of participants were in PreART 
care of which 39% (n=81) had had a CD4 count in the last 6 months. In total 74% 
(n=466) of participants were in appropriate care according to our study definition. 
 
Factors associated with access to appropriate care 
In a multivariable regression analysis (Table 4) sex and age were associated with being 
in appropriate care. Females were 3.78 times more likely to be in appropriate care than 
males (p <0.001;  95% CI: 2.07- 6.90), and those in the age category greater than 45 
years were 4.63 times more likely to be in appropriate care than those in the age 
category 15-24 years (p= 0.002; 95% CI: 1.78-12.01). 
 
Clinic attendance: 
 Of the 627 PLWH 1% (n= 9) reported not having attended a clinic in the last 2 years, 
2% (n=14) in the last year, and 5% (n=29) in the last six months. 77% waited for less 
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to get to the clinic. Where a transport cost was incurred, 65% (n=82) reported that this 
was less than R10. 
Discussion 
According to our definition 94% of participants who were on ART, 64% who were being 
investigated in preparation for ART, and 39% of PreART participants were in 
appropriate care. Of the 627 HIV positive participants 63% reported that they were on 
ART. Thus it appears that in the areas surveyed a high proportion of self reported HIV 
positive people are accessing ART and that access is good with 94% of participants 
being in appropriate care. The ASSA model estimated that in 2011 there were 296 746 
HIV positive people in the Western Cape and 90 179 (30%) were on ART(14). This was, 
however, a projection that included all PLWH, irrespective of whether they knew their 
HIV status or not. In this study the true HIV prevalence was not known.  
Only 64% of participants who were being investigated in preparation for ART had 
attended an ART clinic in the preceding three months. Other studies have also showed 
high rates of attrition in this group. A study in Cape Town reported that  only 67% 
(n=147) of those who returned for a  CD4 count within 6 months of HIV diagnosis and 
who were eligible for ART, were initiated on ART within 6 months of their HIV 
diagnosis(9). A study in Durban examined the loss to care and mortality rates before 
starting ART in ART eligible HIV-infected patients(15). They found that 16% (n=82) were 
lost before ART initiation with 34% (n=28) having died. A large prospective cohort study 
in the Free State, South Africa found that only 34% of eligible patients had started ART 
within 1 year of enrolment(3). 
In the PreART group only 39% had had a CD4 count in the preceding six months. South 
Africa has the most PLWH and the largest ART programme in the world(1, 18). The 
group eligible for ART is large and increased when the South African ART treatment 
guidelines were expanded to include the initiation of ART in PLWH with a CD4 count 
«350 cells/mm3(7, 16). It is essential that PreART patients have regular CD4 counts and 
initiate ART as soon as it is indicated to decrease mortality associated with low CD4 
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care package from HCT through to initiation on ART, specifically with regard to PreART 
care(18, 19). In Cape Town, the policies for PreART care are defined but this has not 
translated into practice with weaknesses in the continuity and quality of the services 
rendered (18). Attention needs to be paid to the PreART programmes to continue to 
strengthen them.  
Our study showed that utilisation of local clinics is good. Only 5% of HIV positive 
participants had not attended a clinic in the last 6 months. Waiting times and transport 
costs do not appear to limit access, with 77% of people waiting less than 4 hours at the 
clinic, and 80% not paying any transport costs. The low proportion of PreART 
participants in appropriate care may be due to both patient and provider factors. 
Patient factors may be related to stigma or denial and prevent PLWH from accessing 
care in the earlier stages of their disease, prior to their becoming ill. Provider factors 
may be a lack of trained staff and the absence of a dedicated implementation program 
for PreART care. Clinic attendance, irrespective of the reason, provides an opportunity 
to target PLWH who are not in appropriate care. A systematic approach to PreART care 
in the clinics is needed and in order to achieve this additional resources need to be 
made available(18). 
 
Men and young adults were less likely to be accessing appropriate care for HIV. This 
finding is also reflected in other studies(3, 11, 20). In a study in rural KwaZulu – Natal,  
retention in HIV care in individuals not yet eligible for ART was associated with a lower 
initial CD4 count, older age and female sex(11). In a large prospective cohort study in 
the Free State, differences in access and patient outcomes across ART treatment clinics 
were assessed(3). Factors associated with not initiating ART included male sex, a CD4 
count below 50cells/mm3, weight below 50kg, and distance to the clinic of greater than 
15km. Factors associated with failure to initiate ART in HIV infected TB patients in an 
integrated TB HIV health care service in Cape Town included male sex, and younger 
age(20). Ongoing targeting of vulnerable groups  such as men and the youth with 
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CD4 testing; and HIV education and awareness campaigns may contribute to improved 
access and retention in care. 
 
There are several strengths to the study. Firstly, the study design allowed us to source 
participants in their homes as opposed to a health care facility. To our knowledge no 
other study determining access to HIV care has sampled in this manner. Access to 
appropriate HIV care could thus be from any health care facility and across any time 
period as opposed to being restricted to clinical records from a specific health care 
facility within a certain timeframe. 
Secondly, 94%of the participants (n=1182) had had an HIV test, and 86% (n=1115) were 
willing to disclose their status. Thus, of the group interviewed, a large proportion was 
able to complete the study questionnaire. 
There are limitations to this study. An objective of the study had been to determine if 
attendance at a health care facility within the last six months for reasons other than 
HIV care was associated with access to appropriate HIV care. During the study it 
became evident that there was often uncertainty as to whether a clinic visit had been 
related to HIV care. This factor was therefore not analysed or reported on. Data was 
however collected regarding a person’s last clinic attendance. Other factors thought to 
impact on access to appropriate HIV care, as detailed under the statistical analysis 
section, were analysed.  
Secondly, it was a self reported study and results that pertain to records such as CD4 
counts and health care facility attendance dates, were not validated. Recall as well as 
reporting bias may influence the results. 97% of the HIV positive group said that they 
had had a CD4 count and 83% knew the value of their first CD4 count. This may be a 
result of reporting bias as other studies have shown much lower proportions. A study 
in Cape Town showed that only 74% of participants had a recorded CD4 count 
measurement in their primary care clinic or hospital records at any time point from 
2004 – 2009(9). Data from a folder review of 634 positive HCT clients, during  a routine 
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taken(18), although it is not known how many clients returned for their results. In 
addition participants were asked if they had ever had a CD4 count as opposed to other 
studies where participants were asked if they had had a CD4 count within a certain 
time period.  
There is limited data available, especially in developing countries, as to the validity of 
self reported HIV status and knowledge of CD4 count as compared to clinical record 
reviews. A study in a developed country found that amongst IV drug users only 68% of 
HIV positive participants accurately reported their HIV status, whereas 98% of HIV 
negative participants accurately reported their status(21). CD4 cell counts were found 
in another study  to be reliably assessed through self reporting in PLWH, especially in 
those with a higher education level(22). In our study we found that most people were 
receptive to talking about their HIV testing and treatment pathway and were 
knowledgeable about their test results. 
A third limitation relates to the sampling frame which was comprised of participants 
from the ZAMSTAR Prevalence survey.  Participants may have been more likely to be in 
appropriate care due to their increased awareness of TB and HIV as a result of their 
exposure to ZAMSTAR.  
 A further limitation was the response rate. 16% (n=250) of the randomly selected 
sample were not found. It is possible that some of these people may have been ill or 
had died from HIV-related illnesses and may have been more likely not to have been in 
appropriate care. Additionally 6% (n=76) of participants who knew their HIV status 
were unwilling to disclose it. These participants may have been reluctant to disclose 
their status to the researchers because they were HIV positive and not in appropriate 
care. The selection biases may affect generalisability of results to PLWH in the rest of 
South Africa. 
Conclusion 
In our study access to appropriate HIV care was high for ART care, however PreART 
care was low. These findings contribute to the growing literature in this field. Clinics 
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their services to access PreART care. In order for this to occur a systematic approach to 
PreART care with attention to client and service factors is needed. The impact on 
existing resources and the need for additional resources to deliver this care should be 
investigated.  
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1547 people were randomly selected 
1297 people were found 250 people were not found 
1257 participants were 
interviewed (81% response rate) 
19 people refused to 
take part  
1191 participants had tested before for 
HIV  (1191/1257 =95%) 
21 people were excluded  
65 participants had never tested for 
HIV before (65/1257=5%) 
1 participant did not know if they had 
tested for HIV 
1182 participants knew their  HIV  
status (1182/1191 =99.2%) 
9 participants did not know their HIV 
status (9/1191=0.8%) 
1115 participants were willing to 
disclose their  HIV  status (1115/1182 
=94.3%) 
67 participants were not willing to 
disclose their HIV status 
(67/1182=5.6%)  
 
487 participants self reported that they 
were HIV negative (487/1115=44%) 
627 participants self reported that they 
were HIV positive (627/1115=56%) 
1 participant excluded due to 
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Table 1: Demographic and HIV testing characteristics of HIV negative and positive 
groups  





























Mean age in years 34 36 P=004 
Age range in years 19 - 71 19-66  
Employment status  p = 0.002 
Unemployed 
Employed part time 


























43 (210)  
31(150) 
15 (73)  
5 (25)  
6 (27)  
0 (2)  
31 (193) 
41 (257)  
20 (124)  
5 (31) 
3 (16)  
1 (6)  
 
Testing place at time of last HIV test  p=0.000 
ZAMSTAR 
Clinic 






41 (200)  
40 (193)  





1 (3)   
47 (292)  
36 (227)  
0 (2 ) 
9 (57)  
7 (43)  




Referral mechanism at time of last HIV test 
(excluding participants who tested at ZAMSTAR ) 
N=287 N=335  
Self referred 
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Table 2: CD4 count testing characteristics 
 
HIV positive group 
N=627 
% (N) 
Participants reporting to have had a CD4 count. 97 (608)  
Participants reporting to have had a CD4 count the same day as testing HIV positive 95 (598)  
Participants reporting to have had collected their  CD4 result 99 (601) 
Participants knowing the value(either precisely or as an estimate) of their first CD4 count 83 (506)  
Participants knowing the value of their first CD4 count precisely 70 (353)  
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Table 3: Access to appropriate HIV care  
 
HIV positive group (n=627)  
Number on ART 392 (63%) 
• On ART & Accessing Care 
• On ART & Not Accessing Care 
94% n=369 
   6% n=23 
Being investigated for ART 25 (4%) 
• Being investigated for ART & Accessing care 
• Being investigated for ART & Not Accessing care 
  64% n=16 
  36% n=9   
Not on ART or being investigated for ART 210 (33%) 
• Not on ART or being investigated for ART & Accessing Care 
• Not on ART or being investigated for ART & Not Accessing Care 
  39% n=81   
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Table4: Factors associated with access to appropriate care 
  UNIVARIABLE MULTIVARIABLE 
  N (%) 
Accessing 
appropriate 
care  N (%) OR 95% CI OR 95% CI 
Total 627 466         
              
Sex     p=0.001   p=0.000   
male 89 (14.2%) 52 (58.4%) 1       




     
  
Agecat     p=0.005   p=0.000   
15-24 52 (8.3%) 36 (69.2%) 1       
25-34 244 (38.9%) 169 (69.3%) 0.946 (0.43 - 2.08) 1.073 (0.579-1.988) 
35-44 234 (37.3%) 178 (76.1%) 1.136 (0.475 - 2.714) 1.637 (0.745-3.597) 
45+ 97 (15.5%) 83 (85.6%) 2.636 (0.905-7.678) 4.627 
(1.784-
12.005) 
              
Referral     p=0.056       
self reffered 187 (29.8%) 134 (71.7%) 1 
  
  
referred by health care 
worker 149 (23.8%) 115 (77.2%) 1.934 (1.041-3.594) 
 
  
referred by ZAMSTAR 291 (46.4%) 217 (74.6%) 1.134 (0.682-1.884)     
              
education     p=0.242       
primary or none 114 (18.2%) 90 (78.9%) 1       
secondary ro tertiary 513 (81.8%) 376 (73.3%) 0.681 (0.358-1.295)     
              
employed     p=0.238       
un-employed 400 (63.8%) 306 (76.5%) 1 
  
  
part time 103 (16.4%) 71 (68.9%) 0.706 (0.434-1.149) 
 
  
full time 124 (19.8%) 89 (71.8%) 0.631 (0.311-1.278)     
              
transport     p=0.743       
other transport  117 (18.7%) 93 (79.5%) 1 
  
  
walk 501 (79.9%) 372 (74.3%) 0.868 (0.372-2.126) 
 
  
missing 9 (1.4%) 1 (11.1%)         
              
transport cost     p=0.728       
no cost (walkers) 501 (79.9%) 372 (74.3%)         
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>R10 29 (4.6%) 25 (86.2%) 1.841 (0.315-10.748) 
 
  
missing 15 (2.4%) 7 (46.7%)         
              
traveltime     p=0.115       
0-14mins 81 (12.9%) 62 (76.5%)         
15-29mins 194 (30.9%) 135 (69.6%) 0.663 (0.381-1.156) 
 
  
30-44mins 200 (31.9%) 149 (74.5%) 0.748 (0.394-1.42) 
 
  
>45mins 143 (22.8%) 119 (83.2%) 1.266 (0.666-2.409) 
 
  
missing 9 (1.4%) 1 (11.1%)         
              
waitingtime     p=0.426       
0-2hr 213 (34.0%) 155 (72.8%) 1       
2-4hrs 271 (43.2%) 209 (77.1%) 1.326 (0.837-2.1) 
 
  
>4hrs 133 (21.2%) 101 (75.9%) 1.292 (0.5-3.336) 
 
  
missing 10 (1.6%) 1 (10.0%)         
              
know HIV+ person     p=0.082       
no one 141 (22.5%) 104 (73.8%)         
someone 483 (77.0%) 362 (74.9%) 0.704 (0.475-1.045) 
 
  
missing 3 (0.5%) 0 (0.0%)         
              
know someone on ART     p=0.362       
no one 209 (33.3%) 146 (69.9%) 1       
someone 416 (66.3%) 319 (76.7%) 1.194 (0.815-1.75) 
 
  
missing 2 (0.3%) 1 (50.0%)         
              
know someone who died of 
HIV     p=0.757       
no one 311 (49.6%) 226 (72.7%) 1       
someone 315 (50.2%) 240 (76.2%) 1.097 (0.61-1.974)   
missing 1 (0.2%) 0 (0.0%)         
              
previous TB treatment     p=0.129   p=0.052   
no 330 (52.6%) 227 (68.8%) 1   1   
yes 297 (47.4%) 239 (80.5%) 1.524 (0.885-2.624) 1.761 (0.995-3.116) 
              
years in community     p=0.731       
<5 years 129 (20.6%) 104 (80.6%) 1       
5-10 years 117 (18.7%) 81 (69.2%) 0.799 (0.331-1.924) 
 
  
>10years 370 (59.0%) 275 (74.3%) 0.722 (0.323-1.617)   
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Please complete for all Participants who give consent to complete this questionnaire. 
 2.1 Completed a questionnaire No Yes 
 2.2 Gave a sputum sample for TB testing No Yes 
 2.3  Tested for HIV No Yes 
 2.4  Had a glucose test No Yes 
 2.5  Was weighed No Yes 
 2.6  Had height measured No Yes 
 
The following questions relate to how you access health care. 
 
Q3.1 In the last two years have you attended a clinic or community health centre (CHC) for: 
(Read aloud each option and mark all that applies.  If they have attended MARK 





1. Antenatal Care 0 2 3 
2. For a chronic disease 0 2 3 
3. To test for TB 0 2 3 
4. TB treatment 0 2 3 
5.  HIV care 0 2 3 
6. Feeling unwell 0 2 3 
7. Trauma 0 2 3 
8. Family planning 0 2 3 
9. For your child 0 2 3 
10. Accompanied someone  0 2 3 
11. Other 0 2 3 
 
If Public or Private to any of the above continue. If No to all go to Q7 
    
Q1 Did you take part in the ZAMSTAR Prevalence Survey in 2010? No Yes 
 If no then probe to be certain that they did not take part, and if they did 
not then thank participant and finish interview. If yes continue. 
 
  
Q2 What tests or procedures did you take part in for the ZAMSTAR Prevalence 
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Q3.2 How many months ago did you last attend for any of the following? 
(Indicate exact number of months on PDA) 
1. Antenatal Care   1 – 60; 99 
2. For a chronic disease 1 – 60; 99 
3.  To test for TB 1 – 60; 99 
4.  TB treatment 1 – 60; 99 
5.   HIV care 1 – 60; 99 
6.  Feeling unwell 1 – 60; 99 
7. Trauma 1 – 60; 99 
8.  Family planning 1 – 60; 99 
9.  For your child 1 – 60; 99 
10.  Accompanied someone  1 – 60; 99 
11.  Other 1 – 60; 99 
 
Q4 The last time you went to the clinic – how did you get there? 
Mark only one option 
1. Walk 1 
2. Taxi 2 
3.  Bus 3 
4.  Own Transport 4 
5. Train 5 
6. Other 6 
If Taxi or Bus or Train option marked continue. Otherwise go to Q5. 
 
Q4.1 What is the cost of a return journey? (999 if unknown) 




   
Q5 The last time you went to the clinic how long (in minutes) did it take in 
travelling time.(both there and back) (include time spent walking to 
where the bus/taxi/train is, waiting for the taxi/bus/train, time used on 
the taxi/bus/train to get to the clinic)?  (999 if unknown) 
 
Time in min 
 
   
Q6 The last time you went to the clinic how long (in minutes) did you spend 
at the clinic (include time spent waiting to get your folder, waiting to be 
seen and waiting for and receiving treatment)?  
(999 if unknown) 
 













Page 69 of 120 
 
 
Q7 Which of the following would best describe your employment situation currently? 
(Mark only one that applies) 
1 .Not working at all 1 
2. Employed full-time 2 
3. Employed part-time  3 
4. Self-employed full-time  4 
5. Self-employed part-time  5 
6. Pensioner  6 
 
Q8  Which one of the following would best describe your current occupation? (Mark only 
one that applies) 
1. Working in formal, salaried employment 1 
2. Working for yourself 2 
3. Casual labour 3 
4. Caring for children or relatives 4 
5. Unemployed 5 
6. General domestic work in your home 6 
7. At school or a student 7 
 
Q 9 The last time you attended the cl nic – did you need to take time off from work or your studies? No Yes  
    
Q10 Do you know someone close to you that has told you that they are HIV positive? No Yes  
  If Yes continue. If No go to Q11. 
 
Q10.1 Who was that person? (Mark all that applies) 
1. Partner No Yes  
2. Child No Yes  
3. Parent No Yes  
4. Sibling No Yes  
5. Another family member No Yes  
6. Close friend No Yes  
7. Other No Yes  
 
Q11 Do you know someone close to you that is on ARV’s? No Yes  
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Q11.1  Who was that person? (Mark all that applies) 
1. Partner No Yes  
2. Child No Yes  
3. Parent No Yes  
4. Sibling No Yes  
5. Another family member No Yes  
6. Close friend No Yes  
7. Other No Yes  
   
Q12 Did you know someone that you were close to that died from HIV? No Yes  
   If Yes continue. If No go to Q13 
 
Q12.1  Who was that person? (Mark all that applies) 
1. Partner No Yes  
2. Child No Yes  
3. Parent No Yes  
4. Sibling No Yes  
5. Another family member No Yes  
6. Close friend No Yes  
7. Other No Yes  
 
The following questions relate to testing for HIV. 
 
Q13 Have you ever been tested for HIV? N Y U  




Have you ever been offered an HIV test? N Y U  
If No or Unknown, then go to question Q13.3, else continue. 
 
Q13.2 If you have been offered a test, but did not test, what was the reason for not testing? 
(Mark all that apply) 
1. Inconvenient.( Did not have time or want to wait to be tested) No Yes  
2. Did not think that I had HIV No Yes  
3. Was scared to know the result No Yes  
4. Did not wish to test because I was worried about the confidentiality of the results No Yes  
5. Did not want it to be known that I had tested for HIV No Yes  
6. Did not understand why it is important to test for HIV No Yes  





















Do you think that you have HIV? N Y RT
A  
 
Thank Participant and finish the interview.  
 
Q14 What was the date you FIRST tested for HIV?  (01/01/1800 if unknown) D D M M Y Y Y Y 
 





What was the date that you LAST tested for HIV?  (01/01/1800 if 
unknown) 
D D M M Y Y Y Y 
 
Q17 Where did you last test for HIV? (Mark only one option) 
1. Clinic/CHC 1 
2. Hospital as an outpatient 2 
3. Hospital as an inpatient 3 
4. Community non medical site 4 
5. Private medical doctor (private general practitioner) 5 
6. Work place 6 
7. Antenatal 7 
8. Zamstar 8 
9. Other 9 
 
Q18 When you last tested for HIV were you:  (Mark only ONE OPTION)  
(Note: Self referred means that you decided by yourself to go to test, rather than a 
health care worker asking you to do so.) 
1. Self referred  1 
2. Referred by health care worker 2 
3. Referred by ZAMSTAR 3 
4. Unknown -5 
 
If Self Referred, answer only 18.1 and then go to Q19, if referred by HCW then only answer 
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Q18.1 Why did you self refer to test?  (Read aloud and mark all that applies) 
1. Wanted to know status No Yes  
2. Partner encouraged me No Yes  
3. Partner was HIV Positive No Yes  
4. Family or friends encouraged me No Yes  
5. Was ill No Yes  
6. Insurance No Yes  
7. Other No Yes  
 
Q18.2 If referred by Health care worker, why were you referred? (Read aloud and mark all 
that applies) 
1. Was ill No Yes  
2. Pregnant No Yes  
3. Diagnosed with Tuberculosis No Yes  
4. Partner was HIV Positive No Yes  
5. Sexually Transmitted Disease (STD) No Yes  
6. Other No Yes  
 
 
The following questions relate to the ZAMSTAR Prevalence Survey. 
 
 
   
 
   If Yes continue. If No go to Q20 
 
The following questions relate to knowing your HIV status. 
 
 
Did you get tested again for HIV at the mobile caravan for the ZAMSTAR Prevalence Survey? No Yes  
If Yes continue If No go to Q20   
Was this the first time that you tested for HIV? No Yes  
If No continue, If Yes go to Q19.3   
Was your HIV result different to the last time that you tested? No Yes  
Did you receive a referral letter for HIV care from the ZAMSTAR VCT staff? No Yes Unknown N/
A  
   
Did you keep that appointment? No Yes  
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   If Positive continue.  IF NEGATIVE FINISH INTERVIEW.  THANK PARTICIPANT. 
 
Q23 What was the date when you were first tested as positive for HIV? D D M M Y Y Y Y 
   (01/01/1800 if unknown) Refer to Timeline to help complete dates 
 
Q24 How many times did you test Negative before you tested Positive? (999 if unknown) NUMBER 
   (Indicate exact number of times on PDA.) 
 
Q25   Where did you test when you were first tested as positive for HIV? (Mark only One 
Option) 
1. Clinic/CHC 1 
2. Hospital as an outpatient 2 
3. Hospital as an inpatient 3 
4. Community non medical site 4 
5. Private medical doctor (private general practitioner) 5 
6. Work place 6 
7. Antenatal 7 
8. Other 8 
 
 
Q26.1 What was the date when you were tested again for HIV?  D D M M Y Y Y Y 
  (01/01/1800 if unknown) 
 
Q26.2   Why did you test again? (Mark only One Option) 
1. Referred by health care worker 1 
2. To reconfirm the results 2 
3. ZAMSTAR study 3 
4. Other 4 
 
 
Are you willing to disclose your HIV status? No Yes  
If YES continue.  IF NO FINISH INTERVIEW.  THANK PARTICIPANT.   
Q22 What is your HIV status? NEG POS  
Q26 Have you been tested for HIV again after you knew you were HIV Positive? No Yes  
 If Yes continue. If No go to Q27   
Q27 When you first tested positive for HIV did you receive counselling on the same day? No Yes  
    
















Please ask the Participant if they have an HIV treatment card available or any other patient 
card or documentation that details their HIV care and fill in the timeline and answer the 





Q30.2 RA ask participant: What was the date of your first CD4 count?  D D M M Y Y Y Y 
  (01/01/1800 if unknown) 
 
Q30.3 RA look at card: Date of first CD4 count documented on card  D D M M Y Y Y Y 
  (01/01/1800 if unknown) 
 
 
Q30.6   Who gave you your results? (Mark only One Option) 
1. Nurse 1 
2. Counselor 2 
3. Doctor 3 
4. Other 4 
5. Unknown -5 
 
Q28 When you first tested positive for HIV was a CD4 count taken the same day that you tested 
positive? 
No Yes  
 If No continue, if Yes go to Q29   
Q28.1 Were you given a referral letter to go and have a CD4 count taken? No Yes  
 If No continue, if Yes go to Q29   
Q28.2 Were you told verbally to go to have a CD4 count taken? No Yes  
 If Yes continue, if No go to Q29   
Q28.3 Did you go to have the CD4 test done? No Yes  
Q29 Is a Patient Treatment card that relates to HIV care available? No Yes  
Q30 RA ask participant:  Have you ever had a CD4 count done? No Yes Un
k 
Q30.1 RA look at card:  Is CD4 count documented on card? No Yes N/A 
Q30.4 Were you given a follow up appointment to collect your results? No Yes Unk 
     



















   If Yes continue directly below, If No go to Q32 
 
Q31.1 
RA ask participant: What was the date of your most recent CD4 
count? 
D D M M Y Y Y Y 
  (01/01/1800 if unknown) 
 
Q31.2 
RA look at card: Date of most recent CD4 count confirmed on 
treatment card  
D D M M Y Y Y Y 




Q30.7 RA ask participant: What was your first CD4 count? Enter the number. (9999 if 
unknown) 
     
Q30.8 Is this a fact or an estimate? F E N/
A 
Q30.9 RA look at card: What was the number of the first CD4 count on the card? (9999 if 
unknown) 
     
Q30.1
0 





If YES, did you keep that appointment? No Yes 
Q30.10.
2 
Was the follow up visit?  (Read aloud and mark all that applies)   
 1. In order to be worked up for ARV’s No Yes 
 2. In order to have a repeat  CD4 test No Yes 
 3. In order to be seen by a Doctor or Health Care practitioner No Yes 
 4. Other No Yes 
Q31 Have you had more than one CD4 count done? No Yes 
Q31.3 RA ask participant: What was your most recent CD4 count? (9999 if unknown)      
Q31.4 RA ask participant: Is this a Fact or Estimate or is it Unknown? F E UNK 
Q31.5 RA look at card: What was the number of the most recent CD4 count on the 
treatment card? 
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  (9999 if unknown) 
 If Yes continue, If No go to Section B (Question 38) 
Section A: The following questions relate to participants who are taking ARV’s. 
Q32.2 RA ask participant: What date did you start ARV’s? D D M M Y Y Y Y 
  (01/01/1800 if unknown) 
Q32.3 RA look at card: Date ARV treatment started on treatment card? D D M M Y Y Y Y 
 (01/01/1800 if unknown) 
Q32.4 RA ask participant: What date did you last go to the clinic for ARV’s? D D M M Y Y Y Y 
(01/01/1800 if unknown) 
Q32.5 RA look at card: Date of last visit on treatment card? D D M M Y Y Y Y 
 (01/01/1800 if unknown) 
Q33 How do you normally get to the clinic to collect your ARV’s? (Mark only One Option) 
1. Walk 1 
2. Taxi 2 
3. Bus 3 
4. Own transport 4 
5. Train 5 
6. Other 6 
If Taxi or Bus or Train continue, else go to Q34
Q33.1 If Taxi or Bus or Train, what is the cost of a return journey? (999 if 
unknown) 
(Indicate exact amount on PDA. Round to the nearest rand.) 
Ammt in 
Rands 
Q34 The last time you went to the clinic how long (in minutes) did it take in 
travelling time (both there and back) (include time spent walking to 
where the bus/taxi/train is, waiting for the taxi/bus/train, time used on 
the taxi/bus/train to get to the clinic)?  (999 if unknown) 
Time in min 
Q32 Are you currently taking ARV’s? No Yes 
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Q35 How long (in minutes) did you spend at the clinic (include time spent 
waiting to get your folder, waiting to be seen and waiting for and 
receiving treatment)? (999 if unknown) 
Time in min 
Q37  Where are you taking your ARV’s? (Mark only One Option) 
1. ARV clinic/community health centre (CHC) 1 
2. Hospital 2 
3. Work place 3 
4. Private clinic/private doctor 4 
5. Other 5 
Continue to Q51 (if Section A completed)
Section B: The following questions relate to being worked up for ARV’s.
(RA explains to Participant that being worked up for ARV’s means that the
Participant is being prepared to start ARV’s.
They are attending counselling sessions and may be having investigations done)
If Yes continue, if No or Unknown go to Q44
Q38.1 Date you last attended the clinic for a reason that was related to being
worked-up for ARV’s? 
D D M M Y Y Y Y 
(01/01/1800 if unknown)
Q39 How do you normally get to the clinic? (Mark only One Option) 
1. Walk 1 
2. Taxi 2 
3. Bus 3 
4. Own transport 4 
5. Train 5 
6. Other 6 
If Taxi or Bus or Train continue, else go to Q40
Q39.1 If Taxi or Bus or Train, what is the cost of a one way journey? (999 if 
unknown) 
(Indicate exact amount on PDA. Round to the nearest rand.) 
Ammt in 
Rands 
Q36 The last time you attended the clinic – did you need to take time off from work? No Yes 
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Q41 The last time you went to the clinic how long (in minutes) did it take in 
travelling time? (Both there and back) (Include time spent walking to 
where the bus/taxi/train is, waiting for the taxi/bus/train, time used on 
the taxi/bus/train to get to the clinic)?  (999 if unknown) 
Time in min 
Q42 How long (in minutes) did you spend at the clinic (include time spent 
waiting to get your folder, waiting to be seen and waiting for and 
receiving treatment)? (999 if unknown) 
Time in min 
Q43   What kind of Health Facility are you going to for your ARV work-up? (Mark only One 
Option) 
1. ARV clinic/community health centre (CHC) 1 
2. Hospital 2 
3. Work place 3 
4. Private clinic/private doctor 4 
5. Other 5 
Go to Question 51 
Q44 If you know your CD4 count to be below 250 then why are you not taking ARV’s? (Read
aloud and mark all that applies)
1. Did not know that I needed to No Yes 
2. Have been on ARV’s before but have stopped No Yes 
3. Don’t think ARV’s work No Yes 
4. Don’t want family or friends to know No Yes 
5. Can’t take time off from work to go to clinic No Yes 
6. Don’t have the time to go to the clinic No Yes 
7. I intend to but have not yet done so No Yes 
8. Don’t Know No Yes 
9. Other No Yes 
10. Not applicable No Yes 
Continue to Question 45
Section C: The following questions relate to preHAART or Wellness Clinic. 
       (RA explain to Participant that preHAART or Wellness Clinic means that they are 
going for HIV care and regular CD4  
  testing and checkups as they do not yet qualify for ARV’s). 
  If Yes continue, if No go to Q51 
Q45.
1 
Date that you last attended the clinic for a preHAART or Wellness 
Clinic? 
D D M M Y Y Y Y 
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 (01/01/1800 if unknown) 
Q46   How do you normally get to the clinic to go to the PreHAART or Wellness clinic? (Mark 
only One Option) 
1. Walk 1 
2. Taxi 2 
3. Bus 3 
4. Own transport 4 
5. Train 5 
6. Other 6 
If Taxi or Bus or Train continue, else go to Q47
Q46.1 If Taxi or Bus or Train, what is the cost of a return journey? (999 if 
unknown) 
(Indicate exact amount on PDA. Round to the nearest rand.) 
Ammt in 
Rands
Q47 The last time you went to the clinic how long (in minutes) did it take in 
travelling time (both there and back) (include time spent walking to
where the bus/taxi/train is, waiting for the taxi/bus/train, time used on 
the taxi/bus/train to get to the clinic)?  (999 if unknown)
Time in min 
Q48 How long (in minutes) did you spend at the clinic (include time spent 
waiting to get your folder, waiting to be seen and waiting for and
receiving treatment)? (999 if unknown)
Time in min
Q50 Where are you going for preHAART/Wellness Clinic?  (Mark only One Option)
1. ARV clinic/community health centre (CHC) 1 
2. Hospital 2 
3. Work place 3 
4. Private clinic/private doctor 4 
5. Other 5 
The following questions relate to disclosure. 
Q51 Have you ever disclosed your status to your (Read aloud and mark all that applies) 
1. Partner No Yes 
2. Family No Yes 
3. Friends No Yes 
4. Community No Yes 
5. Other No Yes 
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6. No One No Yes  
 
 
Q52.1 Were you referred to a support group:  (Read aloud and mark all that applies) 
1. When you tested positive for HIV No Yes  Unk  
2. When you collected your CD4 results No Yes  Unk  




What date did you last attend the support group? (01/01/1800 if 
unknown) 
D D M M Y Y Y Y 
 
Thank the Participant for their time.  RA to ensure that if the Participant is not accessing care 
that they are given information as to which clinic they can visit and given a Referral Letter if 






 d d m m y y y y 
Interviewer           
Study coordinator           
1st data entry           









Q52 Have you ever attended a support group for HIV? No Yes Un
k 
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PARTICIPANT INFORMATION SHEET 
 
TITLE OF RESEARCH PROJECT:  Access to Care Study 
REFERENCE NUMBER: N10/09/291 
PRINCIPAL INVESTIGATOR:  Dr. Elizabeth Du Toit 
ADDRESS:  Access to Care Study, DTTC, Department Paediatric and Child Health, Faculty of 
Health Sciences, Stellenbosch University, Tygerberg Campus. 
CONTACT NUMBER DTTC: Phone 021-9389062; Fax:  021-9389719 
CONTACT NAME AND NUMBER: STUDY MANAGER:  Mr David Nikani ; 021 9389062; Fax: 021-
9389719 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part.  If 
you decide to take part, you will be asked to give written consent before you take part. 
This study has been approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
International Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is the purpose of the study? 
You are invited to take part in a study to determine the factors associated with accessing 
health care.  About 170 people who were past participants in the ZAMSTAR project will take 
part from your community. These people have been chosen at random from all the people who 
participated in the ZAMSTAR survey.  The ZAMSTAR project was conducted from January to 
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within your community.  This is a follow up study to determine if people are accessing health 
care. The study is being carried out in all 8 former ZAMSTAR communities and about 1360 
people will take part in the whole study. The main aim of the Access to Care Study is to 
determine the possible factors associated with accessing health care, specifically with regard to 
HIV care.  This will help us to explore improving access to health care within our country, and 
to present the findings to the relevant health care managers. 
Information on HIV 
The human immunodeficiency virus (HIV) affects the immune system, destroying or impairing 
its function.  The immune system fights infection and disease so that you do not get ill.  HIV is 
mainly spread through unprotected sex with an infected person. It can also be spread if people 
share contaminated needles, syringes or other sharp instruments.  It can also be transmitted 
between a mother and her baby during pregnancy, childbirth and breastfeeding.  Infection with 
HIV is easy to test for and can be diagnosed with a blood sample from a finger prick at your 
local clinic or hospital.  People with HIV normally get ill when they get an opportunistic 
infection.  The most common opportunistic infection affecting people living with HIV and AIDS 
is Tuberculosis (TB).  TB is an infectious disease caused by bacteria (germs), which are spread 
through droplets (coughing).  If you are not diagnosed quickly, you can go on infecting other 
people without knowing it.  TB can be detected with a sputum (phlegm) examination at your 
local clinic or hospital.   
CD4 Count Values 
CD4 cells are a type of white blood cell that fights infection such as bacteria and viruses within 
your body.  CD4 cells are made in the thymus gland, spleen, and lymph nodes, which are the 
infection-fighting system within your body.CD4 cells are destroyed by HIV. 
Your CD4 Count measures the number of CD4 cells in your body. It is measured by taking a 
sample of your blood from a vein in your arm by using a needle.  The CD4 count indicates how 
strong your immune system is and indicates which stage of HIV disease you are in and guides 
when to start ARV treatment for HIV.  Keeping your CD4 count high can reduce infections 
associated with HIV disease and extend your life. 
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Antiretroviral drugs are referred to as ARV’s.  The drugs do not kill HIV, instead they decrease 
the amount of virus in your body until it is very low and does not multiply anymore. In order 
for this to happen you need to take ARV’s everyday at the same time. Currently there are no 
drugs that can kill HIV.  Slowing down the virus slows down the HIV disease.  You need to begin 
ARV treatment when your CD4 count is below 200. If you are pregnant or have TB, then you 
need to start ARV’s when your CD4 count is below 350.  If a person does not yet need ARV’s 
then every six months a CD4 Count should be done at a preHAART or Wellness Clinic to 
determine when ARV’s should be started. 
Treatment and Care 
HIV Counseling and Testing is offered at your local clinic and hospital and in most facilities a 
preHAART (which means pre treatment) or a Wellness Clinic is available for HIV Testing, CD4 
Count Testing, and counselling.  Access to ARV’s is free at your local government clinic and 
local government hospital.  If you seek care at a private clinic or private hospital then there will 
be a cost which is set by that particular institution.   
More about this study 
We will ask you questions to get more details about how you access health care.  This 
information will help us better understand the possible factors associated with accessing care, 
especially for HIV.  We will record your answers to the questionnaires electronically on a 
Personal Digital Assistant (PDA). 
Taking part in this study is voluntary. You will also be given information about HIV, CD4 Count 
Values, and Accessing Care within your community.  You are free to withdraw from this study 
at any stage, without any consequences for you. No financial reward will be given to any 
persons taking part in this study. About 1360 are taking part in the whole study, and about 170 
people from your community are taking part. 
Are there any risks for people who take part in this survey? 
Taking part in this study does not pose any risks to you or your family. However, you may feel 
worried if you need care for HIV and you are currently not in care.  If you need a referral for 
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The following will be required by those taking part: 
1) You will be asked to sign a consent form after you have read and understood this 
information leaflet.  You will be given an original copy of this leaflet and the consent form to 
keep. 
2) You will be asked to complete (with the help of a trained interviewer) a questionnaire about 
how you access care. 
The questionnaire will take about twenty to thirty minutes to complete  
What is the benefit to you by taking part in this study? 
By taking part in this study you will be given health information/education leaflets concerning 
HIV, CD4 Count Values, and Accessing Care within your community.  If you are not in care and 
would like a referral, you will be referred for treatment so that you can keep healthy. 
The information gained from this study will be used to provide suggestions for improving 
health services.  
Quality assurance 
As part of the process of collecting data, we will perform quality assurance on some of the data 
that will be collected.  You may be revisited by other members of the study team who will 
check and confirm that you have been visited by the field study team.   
Confidentiality of information and privacy of the participant 
All personal information obtained during this study will remain strictly confidential.  The 
answers will be transferred to a computer, but your name will not be included, and you will be 
identified by a coded number only. No information about any of the other results will be 
released to any other parties but the research team, without your further consent.  Completed 
questionnaires will be stored in a safe place.  No information regarding personal details which 
could identify individuals or individual households will be disclosed.  Sponsors of the study, 
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The study is funded by the International Union Against Tuberculosis and Lung Disease.  There is 
no conflict of interest between the Principal Investigator and the funders. 
There may, however, be follow-up studies to this study.   In this case personal details may be 
obtained only after further ethics approval and the name may only be made available to the 
principal investigator of the new study. 
The results of this study will be given to the City and Provincial Health departments and also 
published in a medical journal. No names of participants taking part in this study will be 
published or in any way made known. 
Thank you for reading this information sheet.  If you have any questions, please ask them now.  
The interviewer will be pleased to answer them.  If you wish to take part, please read and sign 
the consent form. Please keep this information sheet in a safe place.  You can contact the 
Project Manager as documented at the top of this information sheet if you have any further 
queries or encounter any problems. 
You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 




















Page 87 of 120 
 
 

















Name:   
Address:  
ACCESS TO CARE STUDY:  INFORMED CONSENT FORM  
Declaration by participant   
I confirm that I have read the information sheet, and that the information and procedures 
involved in my taking part in this study have been explained to me. 
1. I understand that I am being followed up from the ZAMSTAR study (Zambia South 
Africa TB & AIDS Reduction Study) which ran from January thru December 2010 for 
this new study called Access to Care. 
2. I give permission for my information from the ZAMSTAR study to be used in the 
Access to Care Study. 
3. I confirm that I have had the opportunity to ask questions about the study and that I am 
satisfied with the answers provided. 
4. I have been given time and opportunity to read the information carefully, to discuss it 
with others and to decide whether or not to take part in this study. 
5. I understand that if it is necessary and should I want one I will be given a referral to the 
nearest clinic for appropriate HIV care, if I am currently not in care. 
6. I understand that I will be given information about HIV, CD4 Count Values, and 
available HIV related access to care in the community. 
7. I understand that the researchers will keep all my personal information confidential. 
8. I understand that at any point I can withdraw from the study without any consequences. 
9. I understand that I will not get any financial reward for taking part in this survey. 
10. I understand that the results of this study will be published in scientific journals but that 
my name will never be used. 
11. I understand that I may in future be requested to participate in follow-up studies but that 
I may decline at a later stage to take part in future studies.  



















Declaration by Participant 
By signing below, I (Please Print)  
(First Name)_______________________________   (Surname) 
____________________________________  
 agree to take part in a research study entitled Access to Care. 
Signed on (date (dd/mm/yyyy)) __________/____________/2011 
 
________________________________                       __________________________  
Signature of participant/(Thumbprint) Signature of witness if needed 
 
Declaration by Research Assistant 
 
I (First Name)___________________________(Surname) _______________________________   (RA 
Code) _________ 
declare that: 
• I explained the information in this document to (name of 
participant)________________________________ and encouraged him/her to ask 
questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
• I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the 
declaration below) 
 
Signed on (date (dd/mm/yyyy)) __________/____________/2011 
 
________________________________                                          
Signature of Research Assistant  
 
Declaration by interpreter 
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I assisted the Research Assistant (name) ______________________________ to explain the information 
in this document  
to (name of participant) __________________________________ using the language medium of 
___________________. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed on (date (dd/mm/yyyy)) __________/____________/2011 
 
________________________________ 
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Access to Care 2011 - Management Form 
     
     
     BARCODE 
       Participant Details: 
   
EA:     Participant Details (change) : 
   
Name           N Y 
Address           N y 
DOB           N y 
       
        
  Date 
Participant 
Found Y/N 
Consent        
Y/R/E/N/P Outcome Date next visit Comments 
Visit 1             
Visit 2             
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HOUSEHOLD BARCODE  INDIVIDUAL BARCODE 
 
SECTION 1 
ALL QUESTIONS IN THIS SECTION MUST BE ANSWERED 
Q01_INC Interviewer’s (RA) code    
  
 















Y   
        
Q03_SEN Serial Number (on HH Management Form)   
  
 
Q04_HOH Are you the Head of Household? No Yes 
  0 1 
 
Q05_SEX Sex M F 
  1 2 
 
Q06_AGE Age (-1 if unknown)    
  
 
Q07_MAR Married to  (Only women to answer – use serial no on HH Management Form)   
  
 
Q08_DIS Disability?    
  No Disability 1 
  Sight(blind/ severe visual impairment) 2 
          Hearing (deaf/ profoundly hard of  hearing) 3 
  Communication(speech impairment) 4 
  Physical(needs wheelchair/ crutches) 5 
  Mental disability 6 
 
Q09_CON Consent No Yes Absent Excluded Pending 
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ONLY CONTINUE IF CONSENT IS GIVEN 
 
SECTION 2A – FILL THIS AND SUBSEQUENT SECTIONS IN ONLY IF PERSON HAS GIVEN 
CONSENT 
  















Y  If not known, what was your age in 
 Q11_1_DOB years at your last birthday? (-1 
if unknown) 
        
 
Q12_YLC How many years have you lived in this community?    




Q13_RAC What is your race?    
 Select only one option Black 1 
  Coloured 2 
  Indian/Asian 3 
  White 4 
  Other 5 
 
Q14_COB What is your country of birth?    
 (Drop down menu with SADC countries and  few other Africa 
countries) 
  
                                                                SA  Nigeria  
                                                       Zambia  Congo (DRC)  
                                                  Zimbabwe  Somalia  
                                                       Malawi                  Other. If other, specify ______________ 
                                            Mozambique         
                                                        
 
Q15_HZS Before this survey, have you heard of or been involved with  DTTC/ ZAMSTAR 





  0 1 
 
Q16_CMS  What is your current marital Status?  
 Never married  1 
 Currently married or living as married 2 
                                                                                                             Divorced or Separated 3 
 Widowed 4 
If never married go to Q18, else continue 
 
Q17_AFM  Age at first marriage? (years, -1 if unknown)  
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18_MOY What has been your main occupation during the past year?    
      
  Unemployed/working on own land 1 
  Occasional/seasonal employment 2 
  Employed (Formal employment or self employed 
making money) 
3 
  Unable  to work 4 
  Student 5 
  Housewife/ home-maker 6 
 








Q19_HES      Have you ever smoked  No Yes 
 If yes continue, if no go to Q20_CDH 0 1 
 
Q19_1_HES     How old were you when you first started regular cigarette smoking? 
            (Age in years; -1 if unknown) 
 
Q19_2_ HES    If you have stopped smoking, how old were you when you stopped?    
             (If the participant has not stopped smoking, current age in years; -1 if unknown) 
 
Q19_3_HES     On average over the entire time that you smoke(d), about how many cigarettes 
per  
                          week do (did) you smoke? (-1 if unknown) 
 
Q19_4_HES On average over the entire time that you smoke(d), do (did) you primarily smoke 
manufactured or hand rolled cigarettes   
 
                Manufactured         Hand Rolled 





Q20_CDH How would you describe your drinking habits?     
  Have never drunk 1 
  Daily drinker 2 
  Occasional drinker 3 




   
I would like to ask you about smoking 
















Q21_HEA                What is the highest level of education you have attained? 
 
  
No formal education 
Grade 1 / Sub A 
Grade 2 / Sub B 
Grade 3 / Std 1 
Grade 4 / Std 2 
Grade 5 / Std 3 
Grade 6 / Std 4 









Grade 8 /Std 6 
Grade 9 / Std 7 
Grade 10 / Std 8 
Grade 11 / Std 9 












If has attended school, continue, if No formal education go to Q23_OCC 
  No Yes Unknown 
Q21_1_FBS Have you ever attended a faith-based school 0 1 -5 
 
Q22_YES When was the last year you were  enrolled in School/College/University? 
(-1 if unknown)  
Y Y Y Y 
 
 
Q23_OCC Please state main occupation at age 15 years?    
  Unemployed/ working on own land 1 
  Seasonal/Occasional employment 2 
  Employed (formal employment or self employed making money) 3 
  Unable to work 4 
  Student 5 
  Housewife/home-maker 6 






  No Yes 
Q24_CTB Are you currently on TB treatment?  Probe and be sure only conventional  




(If yes continue, If No go to Q35) 
Q25_FPS Where did you first present for your symptoms? (Mark only 1 option) 
 
  
  Government/Community clinic 1 
  Private Clinic/hospital 2 
Now I will ask questions about your education  
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  Government Provincial/District hospital 3 
  Pharmacy/Chemist 4 
  Private Doctor 5 
  Traditional Healer 6 
  ZAMSTAR/DTTC Sputum collection point 7 
 
 
Q26_TCA Is TB treatment card available? (confirm by seeing the card) No Yes 
 If yes continue, If No go to Q31 (Record Q27 to 30 from TB Treatment Card) 0 1 
 
 















Y  01/01/1800 if not recorded on card 
 
 
Q28_TTN TB treatment Number (from treatment card, 



















Category of TB as recorded on card?    
  Sputum  smear Positive 1 
  Sputum smear Negative 2 
  Extrapulmonary 3 
  Unknown/not recorded -5 
 
Q30_TTC TB treatment Centre(as written on card)  
 
 
   








Q31_MST Which month did you start treatment  
                                                      January 1 July 7 
                                                    February 2 August 8 
                                                         March 3 September 9 
                                                            April 4 October 10 
                                                             May 5 November 11 
                                                            June 6 December 12 
   Unknown -5 
IF TB TREATMENT CARD NOT AVAILABLE ASK QUESTIONS 31 TO 34, ELSE GO TO QUESTION 35 
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  No Yes Unk 
Q32_SPT Was the sputum smear positive for TB? 0 1 -5 
 
Q33_RTF Where are you receiving your TB treatment from?    
  Government/Community clinic 1 
  Private Clinic/hospital 2 
  Government Provincial/District hospital 3 
   Pharmacy/Chemist 4 
  Private Doctor 5 
 
Q34_TTC TB treatment Centre 






 Previous TB treatment 
Q35_TTB Have you ever been on TB treatment before? No Yes Unk 
  If yes continue, if no go to Q37 0 1 -5 
 
Q36_HMT How many times?     
  Once 1 
  Twice 2 
  Three  3 
  More than three times 4 




  No Yes 
Q37_CHC Do you currently have a cough?  If yes continue, if no go to Q47 0 1 
 
Q38_WBC How many weeks have you been coughing?        
                                                   < 1 week 0 6 weeks 6 
                                                    1 week 1 7 weeks 7 
                                                    2 weeks 2 8 weeks (2 months) 8 
                                                    3 weeks 3 3 – 6 months 9 
                                                    4 weeks 4 >6 months 10 
                                                    5 weeks 5 Unknown -5 
 
I would like to ask about your current state of health 
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Q39_CPS Do you currently produce sputum? No Yes 
  0 1 
 
Q40_CCB Do you currently cough up blood? No Yes 
  0 1 
 
Q41_CAC Did you consult anybody for this cough? No Yes 
 If yes continue, if no go Q47 0 1 
 
Q42_GHF Where did you go for help first? (Mark one only)  
  Government /Community clinic 1 
  Private clinic/hospital 2 
  Government Provincial/ District hospital 3 
  Pharmacy/Chemist 4 
  Private Doctor 5 
  Traditional healer 6 
  ZAMSTAR/D TC Sputum collection point  7 
If checked 1 or 2 or 3 above go to Question 44. 
 
Q43_GCP If pharmacy/private/tradition healer, did you ever go to a 





  0 1 
 
Q44_ASS Did anyone ask for sputum samples? No Yes 




If yes, did you give sputum? No Yes 
 If yes continue, if no go to Q47 0 1 
 
 
Q46_RES What was the result?     
  Negative for TB 0 
  Positive for TB 1 
  Unknown/can’t remember -5 
 
Other symptoms 
Q47_CCP Do you currently have chest pains? No Yes 
  0 1 
 
Q48_CHF Do you currently have fever? No Yes 
  0 1 
Q49_DNS Do you currently have drenching night sweats? No Yes 
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Q50_LWU In the last month have you lost weight unintentionally? No Yes 
0 1 
Q51_DBB Do you currently have difficulty breathing or shortness of breath? No Yes 
0 1 
Individual Barcode 
Q52_THD Have you ever been told you have diabetes No Yes 
If Yes continue, if No go to Q55 0 1 
Q53_CAT If yes, are you currently on any treatment for diabetes? No Yes 
If yes continue If no go to Q55 0 1 
Q54_TON What treatment are you on? 
Dietary only 1 
Tablets 2 
Insulin injections 3 
Q55_KHS Do you know your HIV status? No Yes 
If No and Male, go to Q60.
If No and Female – thank participant and FINISH interview.
0 1 
Q56_DHS Are you willing to disclose your HIV status? No Yes 
If Yes continue, if not willing to discuss and Male go to Q60.
If Yes continue, if not willing to discuss and Female – thank participant and FINISH
interview.
0 1 
Q57_HIV What is your HIV status? 
Negative 0 
Positive 1 
If HIV status is Positive, continue, if Negative and Male go to Q60.   
If HIV status is Positive, continue, if Negative and Female – thank participant and FINISH 
interview. 
Q58_ART Are  you on Antiretroviral treatment( ART) No Yes 
If Yes continue, if No and Male go to Q60. 
If Yes continue, if No and Female – thank participant and FINISH interview. 
0 1 
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Q59_LAR How long have you been on ART?  Write down actual number of months, 
 -1 if unknown 
    
 
Ask question 60 and 61 only to males 
  No Yes Unk 
Q60_CIR Are you circumcised? If yes continue, if no go to Q62 0 1 -5 
 
Q61_WCI At what age were you circumcised?     
 0-10 years 1 
 10-15 years 2 
  15 – 20 years 3 
              >20 years 4 
         Unknown/can’t remember -5 
Thank participant and FINISH interview 
 
INTERVIEWER AND TEAM LEADER TO SIGN OFF QUESTIONNAIRE OVER THE PAGE 
 
 















 d d m m y y y y 
Interviewer            
Team Leader            
1st data entry           
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OPERATIONAL RESEARCH PROJECT    
October 2010 to November 2011   
Name of Project: Access to Care in Peolple living with HIV   
Name of Researcher: Elizabeth du Toit   
                  
                  
  
Categories Item 
No of Units % per 
12 
months 




              
  Study Coordinator  FTE 1 (4months) 33% 
       200 
000  
           84 
000  
            66 
666  8888.8 
  Research Assistant FTE 8 (4 months) 33% 
         40 
000  
           13 
333  
         106 
667  14222.27 
  driver FTE 1 (4 months) 33% 
         75 
000  
           25 
000  
            25 
000  3333.333 
  Data mananger FTE 1 13% 
       300 
000  
           40 
000  
            40 
000  5333.333 
  Data Capturer FTE 
1 (50% 0f 4 
months) 17% 
         60 
000  
           10 
200  
            10 
200  1360 
Total of Personnel Cost       
         248 




            0 
  Vehicle running costs   1   
                   
-    
           20 
000  
            20 
000  2666.667 
  Domestic travel * trips 0         0 
  International travel* trips 0         0 
         District Travel trips 0   
                   
-    
                    
-    
                     
-    0 
Total of Travel and Transportation 
           20 
000  
            20 
000  2666.667 
Equipment 
  
          0 
  Vehicles* unit 0     
                    
-    
                     
-    0 
  PDA*             0 
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 -    -    
Total of Equipment 
                    
-    
                     
-    0 
Materials 
 
            0 
  stationery  unit 0     
             2 
000  
              2 
000  266.6667 
  refreshments for participants unit 0     
                    
-    
            10 
000  1333.333 
  Dissemination meetings unit 0     
             1 
000  
              1 
000  133.3333 
Total of Materials     
             3 
000  
            13 
000  1733.333 
Other Costs  0 
  Printing lumpsum 0     
             2 
000  
              2 
000  266.6667 
  IT Costs* lumpsum 0   
                   
-    
                    
-    
                     
-    0 
  Training         
             2 
000  
              2 
000  266.6667 
  Ethics submission           
              3 
500  466.6667 
  Statistical support lumpsum         
            10 
000  1333.333 
  
Telephone(cell phone 
allowance) lumpsum 0   
            3 
160  
             2 
000  
              3 
000  400 
Total of Other Costs     
             6 
000  
            20 
500  2733.333 
Total  Cost         
         302 
033  40271.07 
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Preplanning for field work 
Finalisation of research protocol 
Submit documentation for ethics 
approval 
Adgudication for review panel 
Project commences 
Advertise and Hire staff 
Train Staff 
Pilot questionnaires 
To develop the tools for analysis 
Design, develop and maintain 
database for data 
Field Work 
Conduct visits and complete 
Questionnaires 
To analyse the data 
Enter and collate data 
Quarterly progress reports to 
mentors 
Submit abstract to IUATLD 
















Write report on findings, discuss 
with stakeholders 
                    
              
Write article based on findings for 
peer-reviewed journal 
                    
              
Finalization of paper and 
presentation at IUATLC 
conference 
                    
              
Dissemination of findings                     
              
Dissemination meetings with 
stake holders, icluding NDOH and 
PDOH 
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any of the 
following 
Discrete 1 = Antenatal care 
2 = For your child 
3 = For a chronic disease (High blood sugar, 
Epilepsy, Diabetes) 
4 = Accompanied someone 
5 = TB treatment 
6 = HIV Care 
7 = Acute Illness 
8 = Trauma 
9 = Family Planning 




Discrete 1 = Walk 
2 = Taxi 
3 = Bus 
4 = Own transport 
5 = Other 
COJ Cost of 
one way 
journey 
Continuous 1 = 1 rand 
2 = 2 rand 
3 = 3 rand 
4 = 4 rand 
5 = 5 rand 
6 = 6 rand 
7 = 7 rand 
8 = 8 rand 
9 = 9 rand 
10 = 10 rand 
To indicate exact amount on PDA (round to 





Discrete 0 = No 
1 = Yes 
DHS.1 Which of 
the 
following 
Discrete 1 = Partner 
2 = Child 
3 = Parent 
4 = Sibling 
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6 = Close friend 




Discrete 0 = No 
1 = Yes 
SAR.1 Which of 
the 
following 
Discrete 1 = Partner 
2 = Child 
3 = Parent 
4 = Sibling 
5 = Another family member 
6 = Close friend 





Discrete 0 = No 
1 = Yes 
TFH Tested for 
HIV 
Discrete 0 = No 
1 = Yes 
DFH Date first 
tested for 
HIV 






Discrete 1 = 1 time 
2 = 2 times 
3 = 3 times 
4 = 4 times 
5 = 5 times 
6 = 6 times 
7 = 7 times 
To indicate exact number of times on PDA 
DLH Date last 
tested for 
HIV 




Discrete 1 = Clinic 
2 = Hospital as Outpatient 
3 = Hospital as Inpatient 
4 = Community HCT 
5 = Private GP 
6 = Work place 
7 = Other (if so list) 
SRH Self 
referred 
Discrete 1 = Self referred 

















3 = Unknown 
SRH.1 If self 
referred 
why test 
Discrete 1 = Wanted to know status 
2 = Partner encouraged me 
3 = Partner was HIV Positive 
4 = Family or friends encouraged me 
5 = Was ill 
6 = Insurance 
7 = Other (if so list) 






Discrete 1 = Was ill 
2 = Pregnant 
3 = Diagnosed with Tuberculosis 
4 = Partner was HIV Positive 
5 = Sexually Transmitted Disease (STD) 
6 = Other (if so list) 





Discrete 0 = No 
1 = Yes 





Discrete 0 = No 
1 = Yes 
-5 = Unknown 




Discrete 0 = No 
1 = Yes 
KHS Know HIV 
Status 
Discrete 0 = No 
1 = Yes 
DHS Disclose 
HIV Status 
Discrete 0 = No 
1 = Yes 
HIV HIV Status Discrete 0 = Negative 























Discrete 1 = Clinic 
2 = Hospital as Outpatient 
3= Hospital as Inpatient 
4 = Community HCT 
5 = Private GP 
6 = Work place 








Discrete 0 = No 











Discrete 1 = Referred by H alth care Practitioner 
2 = To reconfirm the results 
3 = ZAMSTAR Study 





Discrete 0 = No 
1 = Yes 
CDC CD4 count 
done 
Discrete 0 = No 
1 = Yes 
-5 = Unknown 
CDC.1 Date of 
first CD4 
count 





Discrete 0 = No 
1 = Yes 
-5 = Unknowns 
CDC.3 Collected 
results 
Discrete 0 = No 
1 = Yes 
-5 = Unknown 
CDC.4 Who gave 
results 
Discrete 1 = Nurse 
2 = Counselor 
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4 = Unknown 
5 = Other (if so list) 










Discrete 0 = No 








Discrete 0 = No 
1 = Yes 
RAC Referral 
to an ARV 
clinic 
Discrete 0 = No 
1 = Yes 
-5 = Unknown




Discrete 0 = No 





Discrete 0 = No 


















Discrete 0 = No 




Continuous Day, Month, Year 
CAR.2 When last 
gone to 
Continuous 1 = 1 month 















3 = 3 months 
4 = 4 months 
5 = 5 months 
6 = 6 months 
7 = 7 months 
8 = 8 months 
9 = 9 months 
10 = 10 months 
11 = 11 months 
12 = 12 months 
To indicate exact months on PDA 






Discrete 0 = No 
1 = Yes 
-5 = Unknown 
NTA.1 When last 





Continuous 1 = 1 month 
2 = 2 months 
3 = 3 months 
4 = 4 months 
5 = 5 months 
6 = 6 months 
7 = 7 months 
8 = 8 months 
9 = 9 months 
10 = 10 months 
11 = 11 months 
12 = 12 months 






Discrete 0 = No 
1 = Yes 









Continuous 1 = 1 month 
2 = 2 months 
3 = 3 months 
4 = 4 months 
5 = 5 months 
















7 = 7 months 
8 = 8 months 
9 = 9 months 
10 = 10 months 
11 = 11 months 
12 = 12 months 




Discrete 1 = ARV clinic/CHC 
2 = Hospital 
3 = Work place 
4 = Private clinic/Private Doctor 
5 = Other (if so list) 
DYS Disclosed 
status to: 
Discrete 1 = Partner 
2 = Family 
3 = Friends 
4 = Community 





Discrete 0 = No 




any of the 
following: 
Discrete 1 = When tested positive for HIV 
2 = When collected CD4 results 
3 = When referred to ARV clinic 
SGH.2 When last 
did you go 
to support 
group 
Continuous 1 = 0 – 1 month ago 
2 = 2 – 3 months ago 
3 = 4 – 5 months ago 
4 = 6 – 12 months ago 
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Ethics Advisory Group Date:  3rd November 2010 
To:  Dr Elizabeth du Toit 
Title of research project: 
Access to Care in People Living with HIV 
Investigators: 
Dr Elizabeth du Toit, Desmond Tutu TB Centre,  Stellenbosch University 
Blia Yang, DTTC,  
Karen Jennings  City of Cape Town Health Department  
Donald A. Enarson  The Union  
EAG number : 53/10 
Thank you for your application to the Ethics Advis ry Group of the Union.
Your study has our formal approval.
We trust that your study proceeds well and that it will be productive.
With best wishes, 
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rr 
UNIVERSITY OF CAPE TO\xIN 
07 July 2011 
DrE Du Toit 




Dear Dr Du Toit 
Re: Waiver ofHREC Approval 
F acuity of Health Sciences 
Human Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021]4066626 • Facsimile [021]406 6411 
e-mail: shuretta.thomas@uct.ac.za 
The University of Cape Town, Faculty of Health Sciences Human Rcscarch Ethics Committee note that you 
already have research ethics approval from the Human Resea!:ch Ethics Conunittee in the Faculty of Health 
Sciences at Stellenbosch University and the International Union against Tuberculosis and Lung Disease. 
Accordingly, it is not necessary to obtain fw·ther research ethics approval from the Human Research Ethics 
COlrunittee in the Faculty of Health Sciences at the University of Cape Town. 
Yours sincerely 
(O~fb~ 
;;'~FEgSOR M BLOtKMAN 
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